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ABSTRACT  
Background: IPT is an effective, safe and feasible disease prevention scheme that should 
be administered for all PLHIV living in areas with high latent TB prevalence.   
Objective: To assess the impact of isoniazid in the incidence of tuberculosis among HIV 
infected individuals in Addis Ababa. 
Methods: A case control study design was undertaken among 489 HIV and TB infected 
patients in Addis Ababa from January 2008 to December 2010. 
Results: Tuberculosis incidence rate among those who developed TB after completing 6-9 
month isoniazid preventative therapy was17.14 PYO compared to 10.28 PYO among 
those who were not. Isonizide reduced the chance of developing tuberculosis among HIV 
infected patients (OR= 0.072; 95% CI 0.044, 0.12). Age (AOR= 0.14; 95% CI 0.03, 0.97) 
and sex (AOR= 1.86; 95% CI 1.02, 2.23) of the patient, CD4 count at HIV diagnosis 
(AOR= 0.21; 95% CI 0.13, 0.31), clinical stage of HIV illness (AOR= 1.22; 95% CI 1.09, 
1.84) and past tuberculosis history (AOR = 1.97; 95% CI 1.24, 3.67) were major factors 
associated with tuberculosis incidence. 
 
Conclusions: INH prophylaxis was associated with lower incidence of tuberculosis among 
PLHIV.    
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CHAPTER 1 
 
ORIENTATION TO THE STUDY 
1.1. INTRODUCTION  
 
Tuberculosis (TB) is the foremost opportunistic infection associated with Human 
Immunodeficiency Virus (HIV) infection causing a number of deaths (Balcells, Thomas, 
Godfrey-Faussett, and Grant 2006:744). TB and HIV have remained critical public health 
problems for the last three decades. HIV and TB have a synergic effect. HIV suppresses 
immune system and maximizes the risk of tuberculosis infection among people living with 
HIV (PLHIVs). Similarly, TB increases HIV replication which further causes increased viral 
load (Balcells et al 2006:744; Chakaya, Getahun, Granich and Havlir 2008:1).  As a result, 
tuberculosis is the leading cause of morbidity and mortality among PLHVs (Szakacs, 
Wilson, Cameron, Clark, Kocheleff, Muller and McCarthy 2006:1-2; Mosimaneotsile, 
Mathoma, Chengeta, Nyirenda, Agizew, Tedla, Motsamai, Kilmarx, Wells and Samandari 
2010:71; Eldred, Churchyard, Durovni, Godfrey-Faussett, Grant, Getahun and Chaisson 
2010: S1; Mindachew, Deribew, Tessema and Biadgilign 2010:1).  
 
Anti-retro viral therapy (ART) has been found to reduce the risk of tuberculosis infection by 
64% (Golub et al 2009: 634). An observational cohort study done by Lawn and colleagues 
(2010:490) showed that using ART alone is associated with 67% reduction in the incidence 
of tuberculosis. Furthermore Lawn and colleagues described the reduction in the incidence 
of tuberculosis to be proportionately similar both in developed and developing countries.  A 
study in Rio, Brazil, also found that both Isoniazid Preventive Therapy (IPT) and ART were 
effective in reducing tuberculosis infection independently (Golub et al 2007:1445). The 
effect of ART in reducing TB is further supported by Mosimaneotsile et al (2010:71) 
showing ART by itself reduces TB occurrence by 80% among PLHIVs.  A study by Lawn 
(2010:2) also confirmed that ART reduces the risk of acquiring TB by more than 66% in 
HIV infected individuals.  
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IPT reduces the reactivation of latent tuberculosis infection and reduces the risk of 
acquiring TB by 70-90% among HIV co-infected individuals (Cohen, Lipsitch, Walensky 
and Murray 2006: 7042; Golub et al 2007:1441). Individuals who are not enrolled on IPT or 
ART are considerably at higher risk of having new tuberculosis infection and reactivation of 
latent tuberculosis (Akolo, Adetifa, Shepperd and Volmink 2010:2). World Health 
Organization (WHO) recommends use of ART and IPT combination to reduce the burden 
of TB among HIV infected patients (WHO 2010a:5).  
 
In spite of its effect and evidence-based WHO recommendations, use of IPT and its 
integration with HIV programs is very slow in most countries as a result of fearing 
occurrence of adverse effects, INH resistance and lack of knowledge about IPT (Pontali, 
Pasticci, Matteelli, Baldlli and Migliori 2011: 1258; Padmapriyadarsini et al 2011: 854 ) .   
1.2. BACKGROUND TO THE RESEARCH PROBLEM 
 
Tuberculosis is one of the major opportunistic infections (OI) contributing to high morbidity 
and mortality among HIV sero-positive persons. The HIV pandemic has resulted in the rise 
of tuberculosis occurrence affecting the most economically productive age group, 
especially in sub-Saharan Africa countries. The condition is further fuelled by poverty, 
inadequate case detection, diagnosis and treatment, poorly financed health systems and 
the deepening impact of HIV pandemic (WHO 2007:11).    
 
The WHO, Global Tuberculosis Control Report in 2010 showed that 9.4 million new TB 
cases were reported worldwide including the 1.1 million (11.7%) HIV co-infected cases. 
Eighty-five percent of these cases were reported in Asia and Africa: 55% and 30% 
respectively (WHO 2010b:5-7). The same report demonstrated that the mortality among 
380,000 HIV co-infected individuals worldwide, were attributable to tuberculosis. According 
to Golub JE et al (2007:1446), the risk of tuberculosis recurrence in an HIV infected 
individual increases by 19 times due to re-infection or relapse. 
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According to the above report, a total of 1.6 million TB patients with known HIV status were 
reported, of which 47.8% were from Africa. Thirty seven percent of HIV positive persons 
were on ART, whilst, only 80,000 peoples were on IPT. This accounts for less than one 
percent of the estimated HIV co-infected persons in need of TB preventive therapy (WHO 
2010b:16-18).  
 
Out of all Africa countries, South Africa was more effective in IPT program delivery and 
implementation whereby in 2009 alone the country reported 23,583 HIV infected persons 
who have received prophylaxis for TB,  and Namibia and Botswana sited in second and 
third (Getahun, a et al 2010:59). The WHO (2011:138-139) report indicated that South 
Africa took the lead in reaching 124, 049 HIV infected individuals with IPT, which accounts 
79.5 percent of African coverage (WHO 2011: 138-139).   
 
There is growing evidence on effectiveness of ART in reducing HIV related mortality 
(Golub et al 2007:1442; Patel et al 2008: 2; Smart 2009: 2). However, ART alone is not 
sufficient in controlling HIV related TB occurrence. The study by Jonathan and colleagues 
(2009: 632) found that treating PLHIVs with a combination of ART and IPT is more 
effective in reducing TB rate than using ART and IPT separately.   
A prospective cohort study conducted to assess the effect of IPT, ART or both in South 
Africa revealed that ART only reduced the risk of TB by 64%, whereas, the blended IPT 
and ART had 89% impact on reduction of TB hazard (Golub et al 2009:635). Considering 
the convergence of TB and HIV, WHO recommended countries to combine TB and HIV 
collaborative activities together and acclimatize the combined 3‘I‘ measure including: 
Intensive TB case finding (ICF), TB Infection control in health care settings and ART, and 
Isoniazid/INH preventive therapy (WHO 2010c:65; WHO 2011:1; Pontororing et al  
2010:362).  
 
IPT is an effective, safe and feasible scheme that should be administered for all PLHIV‘s 
living in areas with high latent TB prevalence (Granich et al 2010:217; Naidoo, Naidoo, 
Padayatchi and Karim 2011:3). TB preventive therapy has to be administered for 6 months 
to trim down the burden of TB on HIV infected individuals from 33 to 67% (WHO 2010a:5).  
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Studies in HIV infected individuals and other communities who took IPT prior to ART 
showed the effectiveness of INH to prevent tuberculosis (Golub et al 2009:632; 635). 
Clinical trials conducted to measure progress in implementing preventive measures 
implied that IPT use considerably reduced the incidence of TB among HIV infected 
persons (Date et al 2010: 253). Supporting this finding, Granich and colleagues found a 
significant reduction of TB incidence among HIV infected person receiving IPT (Granich et 
al 2010: 218). A research conducted in Brazil showed that incidence of TB among TB/HIV 
co-infected person who received IPT only was 1.27 per 100 Person years of 
Observation/PYO (Golub et al 2007:1444).    
 
Though IPT is effective in reducing TB incidence, the duration of treatment is not well 
studied. A recent study from Botswana found that offering IPT continuously for 36 months 
is much more effective in preventing TB than short course therapy for 6 month. The study 
further showed that, those who received 6 months of IPT had 2.56 per 100 PYO TB risk. 
On the other hand, those who received the 36 month TB preventive therapy had a risk of 
0.19 per 100 PYO yielding 0.08 hazard ratios (Samandari et al 2010: 1588 –1598).  
Samandari and his colleagues (2010:2) reported that there was a 92% decrease in TB 
incidence among those who continuously took INH preventive therapy.  
 
Botswana is the only country in Africa which has a nationwide IPT program.  There are 
controversies around its efficacy in the era of widespread ARV (Anti retro viral) therapy. 
The above study by Samandari et al (2010: 1596) clarified this controversy such that early 
ART can actually do more TB prevention than IPT provision.  The current recommendation 
for IPT is to give IPT to purified protein derivative (PPD) positive TB patients only.  
Botswana is revising its national guideline to fit into this recommendation.  But only few 
countries in sub-Saharan Africa have the necessary financial, human and infrastructural 
resource capacity to adopt a policy of early ART initiation for all PLHV in the near future.  
 
In spite of the good evidence that IPT reduces incidence of TB among persons infected 
with HIV, access to and uptake of preventive therapy is still low (Granich, Akolo, 
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Gunneberg, Getahun, Williams and Williams 2010:S217; Lester, Hamilton, Charalambous, 
Dwadwa, Chandler, Churchyard, and Grant 2010: 45-48; Golub et al 2007:1442). The low 
accessibility and uptake of IPT use results from lack of standard TB screening algorithm 
and guidelines, shortage of IPT supply and challenges regarding competency and attitude 
of health care providers towards IPT (Getahun et al 2010; Lester et al 2010).  
In addition, there are also widespread concerns around duration of IPT protection, INH 
drug toxicity/resistance and adherence to prophylaxis and inability to rule out active TB 
during the screening procedures (Naidoo et al 2011:2; EFMOH 2007c:19; Eldred, 
Churchyard, Durovni, Godfrey-Faussett, Grant, Getahun and Chaisson 2010 1-3; Golub et 
al 2007:1-2). These factors may affect both the perception and attitude of the policy 
makers, health care providers and clients towards INH prophylaxis and its implementation. 
A critical review of health system, political, client related and other barriers should be 
carried out in-order to develop nation specific strategies that are essential to foster 
implementation of IPT program. 
Ethiopia is one of the low income countries in the horn of Africa with an area of 1.1 million 
square kilo meters and the population is estimated at 74 million. The country has one of 
the fastest growth rates at, 2.6% per year and having a total population of 73.8 million 
(Federal democratic republic of Ethiopia: Population census Commission 2008:8-1; 
EFMOH 2009:2). Nearly half of the population is female and life expectancy is relatively 
low at 48 due to high prevalence of HIV and other co-infections (Ethiopia Federal 
HIV/AIDS Prevention and Control Office/FEHAPCO 2010:6).   
Ethiopia is ranked 7th among the 22 listed high burden countries. The incidence of TB in 
Ethiopia is estimated at 579 per 100,000 for all forms of TB and 163 per 100,000 for smear 
positive TB. TB accounts for 7% of deaths (EFMOH 2009:3).  The sero-prevalence rate of 
HIV among adult TB patients is estimated from 20-50% (MOH 2007a:7).  
 
The Government of Ethiopia introduced ART in 2003 and free ART program was started in 
2003 (Kloos, Assefa, Adugna, Mulatu and HaileMariam 2007:45; MOH 2007a: v; MOH 
2007b:1).  
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According to the 2010 country progress report, 511 health facilities were engaged in 
delivering the service and 53% of eligible PLHV were on treatment (EFHAPCO 2010:53). 
The same report showed that out of the 24,112 HIV-positive people referred for TB 
screening, 2,403 (10%) received IPT.  
 
Ministry of health reported 12,926 new cases of tuberculosis in Addis Ababa, the capital 
city of Ethiopia, including 2,723 new smear positive pulmonary tuberculosis cases. The 
number of all forms of tuberculosis was 13, 483 (EFMOH 2008:33). There are nine public 
hospitals serving people infected with HIV and co-infected persons in Addis Ababa.  
 
Similarly, Addis Ababa health bureau (AACCHB) 2010 report showed that the total number 
of tuberculosis cases receiving IPT in hospitals was 1349. Of the nine hospitals, Zewditu 
and Yekatit 12 hospitals are pioneer on starting IPT service by 2008 and eighty percent of 
cases were receiving IPT from these hospitals. They had 613 and 365 cases respectively 
(AACCHB 2010:13).  
The Ethiopian TB/HIV guideline incorporates IPT as the single most important HIV 
preventive strategy. The initiation of IPT is based on laboratory findings, WHO clinical 
staging and presence or absence of contraindications. HIV infected individuals without 
confirmed active TB by clinical or laboratory method could be eligible for IPT. Due to high 
prevalence of TB in Ethiopia, all HIV–infected people with no signs or symptoms of active 
TB and/or negative laboratory (sputum smear or culture) result are eligible for TB 
preventive therapy. But, sero-positive individuals who are categorized in either WHO 
staging III or IV or symptomatic patients will be excluded from receiving IPT. Cognizant to 
this, those clients with active tuberculosis, abnormal chest X-ray, active hepatitis, known 
high daily alcohol consumption, prior allergy or intolerance to INH and history of close 
contact with Multi Drug Resistant–tuberculosis (MDR-TB) patient are not entitled to take 
IPT (EFMOH 2007c:18).  
 
ART program is implemented across the country; however, the coverage of TB/HIV 
integration in health facilities is not optimal enough to tackle the burden of tuberculosis 
(EFMOH 2007b:2). Besides, the impact of IPT on reducing tuberculosis incidence among 
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HIV infected individuals is not well documented. Hence; this research intends to assess 
the impact of IPT on TB incidence among HIV infected persons in public hospitals of Addis 
Ababa. 
1.3. RESEARCH PROBLEM  
 
WHO recommends that IPT provision for HIV infected persons, particularly in areas where 
the HIV prevalence among TB patients is 5% or more (EFMOH 2007c:17). The prevalence 
of HIV among TB patients in Ethiopia is estimated to reach around 40-70% (Deribew, 
Tesfaye, Hailmichael, Negussu, Daba, Wogi, Belachew, Apers and Colebunders 
2009:105; Datiko, Yassin, Chekol, Kabeto and Lindtjørn 2008:1). 
 
A cohort study conducted in Arba-Minch Hospital, South Ethiopia, showed a TB incidence 
rate of 9.9 per 100 person-years of observation (PYO) which is twice more than a research 
finding from factory working PLHIVs in Ethiopia (Jerene 2007:43). The same study showed 
that PLHIVs on pre ART care had TB incidence rate of 11.1/100 PYO compared to those 
on ART (3.7/100 PYO). Among PLHIVs started ART, the incidence of TB decreases from 
first to fifth year of treatment (Jerene, Naess, and Lindtjorn 2006:3; Jerene et al 2007:45). 
 
INH preventive therapy is cost effective, safe and feasible drug of choice to reduce the 
incidence of TB among HIV infected persons especially in resource limited settings 
(Granich et al 2010:217; Naidoo et al 2011:5; WHO 2011:16). However, several 
challenges associated with its implementation limit the benefit of this public health strategy 
in Ethiopia.  These challenges are rooted in the weakness in the country‘s health system, 
societal beliefs and norms and patient knowledge, attitude and behaviour. Health 
resources and services are not sufficiently available and their distribution is not equitable.  
If available, the quality of service delivery is generally not optimal.  There is a widespread 
misconception on INH resistance and side effects both among health workers and patients 
(EFMOH 2007c:19).    
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The knowledge about IPT effectiveness in reducing TB incidence among HIV infected 
persons might help in the scale up of the service. However, public health importance of 
INH Preventive Therapy in preventing TB occurrence among PLHIV is not well studied. 
The main focus of this study is to assess the helpfulness of IPT in reducing the rate of TB 
among PLHIV in Ethiopian context. 
1.4.  PURPOSE OF THE STUDY 
1.4.1. Research purpose  
The main purpose of this study is to assess the impact of INH preventive therapy on the 
incidence of tuberculosis among TB and HIV co-infected individuals in Zewditu and Yekatit 
12 hospitals in Addis Ababa, Ethiopia 
1.4.2. Research objectives  
The specific objectives of this research were  
 To compare  the incidence of TB among HIV infected clients who received IPT and 
those who did not 
 To determine the socio-demographic and behavioural factors associated with TB 
incidence among HIV infected patients 
 To compare HIV disease related factors associated with TB infection among those 
who received IPT and those who did not 
1.5. SIGNIFICANCE OF THE STUDY  
 
The findings of this study is to contribute to the existing knowledge of IPT effectiveness by 
comparing the incidence of TB among HIV infected persons who received INH prophylaxis 
and those who don‘t  in Ethiopian context. It would also provide information on IPT 
program implementation and its challenges for health planners and managers.  
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1.6. DEFINITIONS OF TERMS  
 
For the purpose of this specific study, the following terminologies were used.  
 Active Tuberculosis: TB that has been confirmed by clinical and positive sputum 
smear or chest x-ray result suggestive of TB.    
 Cohort study: is type of study that begins with a group of peoples who are free of 
disease and similar exposure status are followed for a certain period of time.                                                                           
 Defaulter: A patient whose INH Preventive Therapy was interrupted for 2 
consecutive months or more. 
 Epidemiology: is the study of the frequency, distribution and determinates of 
health-related conditions and events in a specified populations, and the application 
of this study to the control of health problems.      
 Isoniazid preventative therapy (IPT) completed: An HIV infected person who 
took Isoniazid (INH) for a course of six months without interruption with a maximum 
dose of 400mg/day aiming to prevent development of tuberculosis.  
 Prospective Cohort study: is a type of cohort that starts the study with the 
identification of the population and the exposure status and follows them for the 
development of the outcome factor. 
1.7.  LIMITATIONS 
 
The study is retrospective analysis of patient records. Firstly, the research will utilize 
secondary data abstracted from TB/HIV treatment forms, which may be incomplete. 
Secondly, the study will include TB/HIV co-infected individuals from selected public 
facilities, which may not include patients managed in private sector. Thirdly, this data is 
most likely to be limited to patients residing in Addis Ababa and its environs who cannot 
represent other patients from the rest of the country.  These factors reasons may reduce 
the validity and generalize-ability of this study.  
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1.8.  OUTLINE OF THE STUDY 
 
Chapter 1 describes the background to the research problem and the research problem, 
purpose and significance of the study, and limitations of the study. 
Chapter 2 covers the literature review.  
Chapter 3 describes the research design and methodology used. 
Chapter 4 presents the data analysis and interpretation of findings including discussion  
Chapter 5 concludes the study findings, discusses its limitations, and makes 
recommendations for practice. 
1.9.   CONCLUSION 
 
Tuberculosis is the leading opportunistic infection associated with HIV infection.  INH 
preventive therapy is effective and significantly reduces the occurrence of tuberculosis 
infection among HIV infected individuals.  The helpfulness of IPT in reducing the rate of TB 
among PLHIV in Ethiopian context not well studied in Ethiopia. This chapter briefly 
described the background of the problem; and purpose, objectives and significance of the 
study and definition of terms. The researcher described the ethical considerations upheld 
and defined key terms.  
 
Chapter 2 covers the literature review conducted for this study.  
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CHAPTER 2 
 
LITERATURE REVIEW 
 
2.1. INTRODUCTION 
 
This chapter discusses the literature review on TB and HIV co-infection, including the 
background and history, the description, treatment and prevention of the disease which 
can be added to the knowledge, awareness and practices regarding TB and the 
programmes related to TB control. 
Researchers carry out a literature review to understand and extend their knowledge of the 
phenomenon under study. According to Polit and Beck (2007:88- 89) literature review is 
intended to understand the nature and meaning of the problem under study clearly. 
Cognizant to this, literature review assisted the researcher in exploring the knowledge and 
findings regarding TB and HIV co-infection, IPT and the impact of INH preventive therapy 
in reducing tuberculosis incidence  in an to attempt to minimize the knowledge gap in this 
area of public health in Ethiopia  
Generally, the purpose of this literature review was to: 
 Ensure that previous studies are not duplicated.  
 Describe recent research developments on the subject.  
 Find out the most widely accepted empirical findings in the field of study.  
 Identify the available study instruments that have proven high validity and reliability.  
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2.2. TUBERCULOSIS  
2.2.1. Global burden of Tuberculosis  
Tuberculosis is a contagious airborne disease caused by Mycobacterium tuberculosis 
bacteria and transmitted when individuals with infectious TB come into in contact with 
healthy individuals at different settings (WHO 2010a: 6; Roeger, Feng and Castillo-Chavez 
2009: 815-837; Halima 2011:1). Both HIV infected and non-infected individuals can 
acquire Tuberculosis, even though there is a difference in incidence. Tuberculosis (TB) is 
the leading opportunistic infection associated with Human Immunodeficiency Virus (HIV) 
infection causing a number of deaths (Balcells et al 2006:744). Specially, the burden of TB 
is common in people living with HIV in developing countries (Szakacs, Wilson, Cameron, 
Clark, Kocheleff, Muller and McCarthy 2006: 1). It is estimated that more than 2 billion 
people have latent TB infection worldwide, which almost accounts for 32% of the world 
population (WHO 2008:293; Roger et al 2009: 816).  
 
In 2010, worldwide, there were an estimated 12 million prevalent TB cases, which is 
comparable to 178 cases per 100,000 populations (WHO 2011b: 5-7; 9-13). According to 
WHO inference, in 2010, there were 8.8 million new TB cases globally, which equates to 
128 cases per 100,000 populations. TB incidence is decaling from 2004, 142 cases per 
100,000 to 137 in 2009 and 128 new cases per 100,000 populations in 2010.  Though 
there is a decrease in TB incidence, tuberculosis is still among the top three greatest 
causes of death among the population (WHO 2011b: 5-7; 9-13).  
 
Despite the fact that TB is a curable disease, an estimated mortality of 1.7 million in 2009 
and 1.45 million, occurred in 2010, showing a remarkable decline (Mohammed 2011:1). 
Out of these 1.45 million deaths, 1.1 million TB deaths were among HIV uninfected 
patients and 0.35 million (24.14%) deaths were HIV infected patients.  The overall death 
rate among HIV infected and HIV uninfected TB patients also shows a decline from 26 
deaths per 100,000 populations in 2009 to 15 deaths per 100,000 populations in 2010.  
(WHO 2011b:5-7; 9-13).  
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2.2.2. Burden of tuberculosis in Africa 
Tuberculosis is the major cause of AIDS allied mortality among people living with HIV, 
accounting for 26% of all deaths and 99% of these deaths occur in developing countries.  
Africa a home for not more than 11% of the world population shares one third of global 
tuberculosis burden (Africa Union /AU 2006:1-3).  Developing countries, where ninety five 
percent of new TB cases and ninety nine percent of death occur, are predominantly 
affected region (Mohammed 2011:1).  .   
Tuberculosis is the major burden in developing countries, especially in sub-Saharan Africa. 
More than two-third (34) countries have at least 300 cases per 100,000 population TB 
notification rates which is more than 20 times (less than 15 cases per 100, 000 population) 
higher than the developed world (AU 2006:2). The World Health Organization Global 
Tuberculosis report indicated that, of the estimated 8.8 million incident cases in 2010, 2.29 
million (26%), were in Africa.  The number of prevalent cases in the same reporting period 
was 2.5 million and mortality was 30 cases per 100, 000 populations (WHO 2011b:9-13).  
 
According to Moore and colleagues (2007:713-719), TB accounts for up to 11% of AIDS 
related death worldwide and case fatality rate for TB among HIV infected patients are 
extremely high reaching up to 40% in sub-Saharan African countries. Besides, the rates of 
recurrence after the completion of treatment is up to 20 per 100 person years in sub 
Saharan Africa (Crampin, Mwaungulua, Mwaungulu, Mwafulirwa, Munthali, Floyd, Fine 
and Glynn 2010: 417).      
2.2.3. Burden of TB in Ethiopia  
Ethiopia is among the countries hardly affected by tuberculosis. The global WHO report 
estimated 0.3 million incident TB cases and 54,000 TB related mortality in Ethiopia in 2009 
(WHO 2010b:5). The Ethiopian Federal Ministry of Health estimates 579 per 100,000 
population occurrence of all forms of TB in the country annually (163 per 100,000 for 
smear positive TB) and TB accounts for 7% of deaths (EFMOH 2009:3). 
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 The recently released Global TB Control Report (WHO 2011: 9-13) showed that the 
current TB prevalence rate in Ethiopia is estimated at 394 cases per 100, 000 population, 
more than 46% lower from the national estimate in 2009, whereas, the incidence rate was 
262 cases per 100, 000 population. The same report showed a relatively higher level of 
death related to TB in Ethiopia which accounts 35 cases per 100, 000 populations 
2.3. TB/HIV CO-INFECTION 
2.3.1. TB/HIV interaction 
HIV associated TB poses the majority of disease burden worldwide in general and in 
resource-limited settings specifically in particular (Padmapriyadarsini et al 2011:850; 
Pawlowski, Jansson, Sköld, Rottenberg and Källenius 2012፡ 1; WHO 2012: 8).  
Tuberculosis and HIV have synergistic biological outcome and profound effect on the 
immune system. The co-existence of these diseases compromises the immune system. 
TB is the commonest opportunistic infection occurring among immuno-compromised 
individuals including HIV and AIDS (Padmapriyadarsini et al 2011:850). The risk of 
developing tuberculosis among immuno-compromised individuals is higher than their 
immuno-competent counterparts. People living with HIV have 21-34 times more risk of 
developing TB than those without HIV infection (Pawlowski et al. 2012: 1-3).  Individuals 
who are co-infected with HIV have 20-50% more risk of developing active form of 
tuberculosis than HIV negative individuals. The co-infected people are at a greater risk of 
dying due to late diagnosis and treatment.  According to World Health Organization, 90% 
HIV individuals who are untreated will die within months of co-infection (Nieburg, 
Ramachandran and Hofler 2008: 2).   
 
2.3.2. Epidemiology 
Gao and colleague (2010:1) reported that stated that more than one-third of the 33.3 
million people living with HIV (PLHIV) worldwide in 2007 were co-infected with TB 
approximately, and close to 80% of the live in sub-Saharan Africa. 
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According to World Health Organization report (2010:7), the HIV-prevalence among TB 
incident cases is 12% globally. The least co-infection rate is reported from the eastern 
Mediterranean region which is 1.6% and 37% reported as the highest. A recent hospital 
based retrospective cross-sectional analyses study in Dar es Salaam, Tanzania showed 
that more than 90% of TB patients were also co-infected with HIV. Contrary to this, a study 
done in mainland China showed that only 0.9% of HIV sero-prevalence among TB patients 
(Geo et al 2010:2).  
In the case of Ethiopia, there is a dearth of information regarding TB/HIV co-infection. 
According to Jeren (2007:7), TB/HIV co-infection rate of Ethiopia is about 45% among 
sputum-smear-positive pulmonary TB patients. In 2009, the global tuberculosis control 
report indicated that HIV sero-prevalence among TB cases was 12%, which equals the 
global co-infection rate. A cross-sectional study conducted to evaluate the TB/HIV 
collaborative activities at the capital city of Ethiopia in Addis Ababa (2012:1-6) showed 
that, 24% of TB patients were HIV sero- positive. The same report showed that among HIV 
infected individuals who participated in an exit interview, 52.1% were co-infected with 
tuberculosis in the past 3 years after learning their HIV sero status (Kassa, Jerene, Assefa, 
Teka, Aseffa and Deribew 2012: 1-6).   
2.4. COLLABORATIVE TB/HIV ACTIVITIES   
The collaborative TB/HIV activities policy was formulated by World Health Organization in 
2004 to provide well established framework for countries in their response to HIV-related 
TB. The recently updated collaborative TB/HIV activities policy recommends national 
programmes and other stakeholders to incorporate TB/HIV activities into routine HIV 
prevention package. The aim of collaborative TB/HIV activities is to reduce the dual burden 
of TB and HIV in people living with the disease or at risk of disease. In order to achieve 
this goal, WHO TB/HIV collaborative activities were made to scale up the three ‗I‘s - 
intensified TB case-finding (ICF), Isoniazid preventive therapy and TB Infection control in 
health-care facilities and congregate settings (WHO 2012:14-30).  
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2.4.1. Isoniazid preventive therapy (IPT) 
WHO and International Union against TB and Lung Disease (IUTLD) recommended the 
use of IPT in reducing TB among HIV infected persons since 1993, which was further 
revised and strengthened in 1998. In 2004 the TB/HIV collaborative activities were 
introduced. INH preventive therapy is given to those with latent tuberculosis infection in 
order to prevent development to active disease. Isoniazid preventive therapy (IPT) is a 
daily self-administered therapy for at least 6 months for all eligible PLHIVs (EFMOH 
2007c:18). IPT should be initiated based on the WHO clinical staging, laboratory and 
clinical findings, and presence or absence of contra-indications (EFMOH 2007c:18). It 
could be mandatory to exclude active, which is a major challenge for health care providers, 
from of tuberculosis before prescribing IPT.  
Studies showed that IPT is effective and safe preventive method that reduces the 
incidence of TB and death among HIV infected people. WHO strongly suggest patients 
living with HIV should be screened for active TB, should not have current cough, fever, 
weight loss or night sweats; and adolescents and adults living with HIV with unknown or 
positive tuberculin skin test (TST) status should obtain at least 6 months of IPT. IPT should 
be accessible to persons on ART, PLHIV‘s with-out considering the extent of 
immunosuppression, and also to those who have formerly been treated for TB and 
pregnant women. Before the administration of IPT exclusion of active TB and absence of 
present cough, night sweats, fever, or weight loss should be made (WHO 2012: 24).  
2.4.5. Current IPT Program Practices  
2.4.2.1. Global 
According to the global TB control (WHO 2010:18), in 2009 around 80, 000 HIV positive 
people were provided with IPT, which accounts for less than 1% of the estimated number 
of eligible people living with HIV.  
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Afterward, in 2010, the global number of HIV positive individuals without active TB who 
enrolled on IPT was estimated at 180,000, which is seven times significant to the level 
achieved in 2005 and three-fold in 2008. High burden countries contributed to more than 
ninety four percent to this figure and of which eighty nine percent (160,000) of individuals 
were from Africa. WHO classified forty-one countries as high burden countries, 29 of which 
are from Africa continent (WHO 2010:18).  
2.4.2.2. Ethiopia 
The Ethiopian and WHO TB/HIV implementation collaborative activities guideline 
recommends IPT for people living with HIV with unknown or positive tuberculin skin test 
(TST) status and are unlikely to have active TB, those who screened with a clinical 
algorithm; those who do not present with any one of the symptoms of current cough, fever, 
weight loss or night sweats (EFMOH 2007c: 17-18; WHO 2012:23).  The Ethiopian 
guideline recommends a self-administered Isoniazid at a dose of 5mg/kg with a maximum 
dose of 300mg/day for six months (EFMOH 2007c:18; Marais, Zyl, Schaaf, Aardt, Gie, 
Beyers 2006: 762-764; Mindachew et al 2011: 1).  
 
In 2005 the number of HIV infected person who were provided with IPT were only 1983 
and 2403 in 2009 (WHO 2010). A recently released report by WHO (2011:62) states that 
of 43, 837 HIV infected individuals screened for TB, 6,636 were enrolled on IPT in 2010 in 
the whole Ethiopia. IPT is an integral part of the routine HIV and TB prevention package in 
most health care setting (EFMOH 2007c:18).  
 
2.4.5. Scientific Consensus on IPT 
Providing ART and IPT helps in reducing the effect of tuberculosis among people infected 
with HIV. Though ART is the major strategy to reduce opportunistic infections including TB, 
studies suggest that using IPT together with ART will have strong impact on reducing TB 
recurrence and activation.  However, using ART and IPT among HIV-infected patients with 
positive TST, reduced the risk of TB infection by 90% (WHO 2012: 24). 
 
18 
 
Effective Anti-retroviral therapy (ART) reduces TB incidence significantly among HIV 
infected individuals. A study from South Africa has shown that ART reduces the incidence 
of TB by two-third among HIV infected individuals (Lawn 2010: 2; Golub 2007:1441-1442; 
Patel et al 2008: 57-508). The world health organization on its TB/HIV collaborative 
activities policy states that ART risk of TB by the population-based risk of PLHIV by 27% to 
80% and TB recurrence rate by 50%. A recent clinical trial conducted in Botswana, also, 
found that early initiation of ART alone reduce the risk of TB by 80% (WHO 2012: 24). 
Despite the fact that ART is increasingly becoming accessible and successful in reducing 
HIV related deaths, tuberculosis remains the leading cause of mortality and morbidity 
among PLHIV and an intimidation for countries (Charalambous, Grant, Innes, Hoffmann, 
Dowdeswell, Pienaar,Fielding and Churchyard 2010: S5; Cohen, Lipsitch, Walensky and 
Murray. 2006: 7042 , Pawlowski et al 2012:2).   
 
A prospective cohort study by Golub et al (2009: 631) showed that using a combination of 
ART and IPT among PLHIVs is more effective in reducing latent TB infection than using 
discretely. Jonathan and colleagues‘ study showed that the rate of TB infection was 
reduced in PLHIVs who were on either IPT or ART (Golub et al 2009:631; 635; Nieburg et 
al 2008:2).  These findings were further supported by Mosimaneotsile and colleagues 
study illustrated that providing IPT together with ART may lessen the incidence of TB by 
additional 58-76% (Mosimaneotsile et al 2010: 71).    
 
Studies suggest that TB preventive therapy is not only effective against TB incidence, it 
also reduces rate of mortality related to TB. A study from South Africa has revealed that 
the death rate within the first three months after the instigation of ART among those who 
were not on IPT (20.15 PYO) was higher compared to those on IPT (6.65 PYO) 
(Charalambous et al 2010:S9-S10).  Similarly, a randomized control trial study by Zar and 
colleagues (2006: 1-7) also showed that a death rate of 5.9% among PLHIV‘s who took 
IPT and 21.3% among those who don‘t receive.  
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A randomized controlled trial study conducted in 2006 showed that the incidence of 
tuberculosis among the INH group (3.8%) was lower than in the placebo group (9.9%) 
using intention to treat analysis. Besides, the same research pointed out that the rate of 
death among children infected with HIV and grouped under INH was lower than that of the 
placebo group (Zar et al 2006:1). A similar finding was reported by Golub and colleagues 
in 2009, IPT independently reduces TB incidence by 70-90% in peoples infected with HIV 
(Golub et al 2007: 1441). Supporting this finding, Padmapriyadarsini and colleagues found 
that taking IPT daily for six months reduces the rate of TB by more-than 67% among HIV 
infected individuals (Padmapriyadarsini et al 2011: 854).  
 
Despite the fact that IPT is effective in reducing tuberculosis, different studies showed 
individuals who received continuous IPT had better outcome than those who took for short-
term. A study by Samandari and colleagues found that PLHIVs who received continuous 
IPT had 92% reduction in TB incidence. Supporting this finding, a study from Botswana 
revealed that providing a daily based IPT for 36 months is much more effective in reducing 
incidence of TB among HIV infected persons than 6 months do. The same study showed 
that those PLHIV‘s who received 36 months IPT had a risk of only 0.19 per 100 PYO, 
whilst, those who took 6 months of IPT had 2.56 per 100 PYO tuberculosis risk 
(Samandari et al 2010: 1588).  
2.4.5. Concerns Related to IPT 
Despite the availability of policies and recommendations and significant evidence that IPT 
reduces incidence of tuberculosis (TB) in HIV-infected individuals, the utilization of IPT is 
still lower than expected due to diverse arguments. The uptake and delivery of INH 
preventive therapy is disappointingly slow in most countries. Lack of standard operating 
procedures, guidelines and screening algorithms, lack of health care provider capacity in 
providing the service, and shortage of preventive therapy supplies contributes to the low 
availability and poor uptake of IPT (Granich et al 2010:S216; Lester et al 2010:S45-S48; 
Golub et al 2007:1441; Eldred et al 2010: S1; Gao et al 2010: 1-2; Mosimaneotsile et al 
2010: 71).  
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Furthermore, there is a wide spread concern regarding side effects, complexity to rule-out 
active TB case and duration of IPT protection. INH drug toxicity, poor adherence to IPT, 
fear of INH resistance and patient driving factors including pill burden, non-adherence, 
economic status and unfamiliarity about IPT are also contributing factors for low delivery 
and uptake of IPT (Zanoni, Phungula, Zanoni, France and Feene 2011: 50; EFMOH 
2007c:19, Eldred et al 2010:S1; Golub et al 2007:1441-1442; WHO 2008:23-24; Lester et 
al 2010: S45–S48).  
INH preventive therapy when used to treat latent TB infection doesn‘t promote INH 
resistance. A study done in Addis Ababa, Ethiopia, found that the most-important cause for 
INH preventive therapy failure is poor adherence (Mindachew et al 2011:2).  The study by 
Padmapriyadarsini et al (2011: 850-865) also indicated that there is no study on IPT that 
reported greater INH resistance rate exclusively attributable to IPT.  
Besides, a cluster randomized trial conducted by Grant and colleagues (2010:S29-S36) 
showed that the low performance of IPT program has been primarily due to fear of adverse 
effects. Among 24, 221 study participants, 61 (0.25%) developed mild-to-moderate degree 
of hyper-sensitivity, 50 (0.21%) peripheral neuropathy, 17 (0.07%) hepatotoxicity and 4 
(0.05%) had convulsion.  It was clear that the risk of INH prophylaxis related adverse effect 
particularly hepatotoxicity, was very low (Grant et al 2010: S29-S36). 
2.4.5. IPT recommendation 
IPT is recommended for HIV infected individuals without active TB infection. The Ethiopian 
TB/HIV guideline recommends IPT for all Individuals who are HIV infected, including 
pregnancy, except for individuals with any one or more of the following conditions. A 
person with active tuberculosis, symptoms compatible with tuberculosis, even if the 
diagnosis of TB cannot be confirmed, abnormal chest X-ray, diagnosis and treatment of TB 
in the past 3 years and cases where poor treatment prognosis is expected (i.e.) - terminally 
ill AIDS patients, history of poor compliance with treatment, active hepatitis, known or 
reported high daily alcohol consumption, prior allergy or intolerance to isoniazid, and 
history of close contact with MDR-TB patient are not eligible and should not receive IPT 
(EFMOH 2007c :18; WHO 2008:23-24).  
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CHAPTER 3 
 
RESEARCH DESIGN AND METHODOLOGY 
3.1. INTRODUCTION 
 
In this chapter, the study design and data collection method will be discussed in detail, 
covering population and sampling, the instrument, data collection and analysis, ethical 
considerations and issues around study reliability and validity. 
3.2. RESEARCH DESIGN 
Polit and Beck describe research design as the overall plan for obtaining answers to the 
questions being studied and for handling some of the difficulties encountered during the 
research process (Polit and Beck 2008:49; 730). The choice of study design determines 
how the researcher samples the population, collects measurements and analyses the 
data. A quantitative, descriptive study case control study design was chosen for this study. 
The main purpose was to assess the impact of INH preventive therapy on the incidence of 
tuberculosis among TB and HIV co-infected individuals in Addis Ababa, Ethiopia.  
 
3.2.1. Quantitative studies 
Broadly speaking, quantitative studies is a type of empirical research that focuses on 
numeric information that results from structured measurement of occurrences and that is 
analyzed using statistical procedures. Besides quantitative methods are formal, objective, 
systematic procedure in which numerical data are used to obtain information about the 
reality. Quantitative researchers‘ uses data in numeric form (Polit and Beck 2008: 15-16; 
33; Bruce, Pope and Stanistreet 2008: 1-7).  
This study collected quantitative data of HIV infected and TB patients who were enrolled 
on IPT and those who were not using patient record reviews.  
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3.2.2. Descriptive Study 
Descriptive study designs observes, classify, count and describes characteristics of a 
condition without affecting its natural occurrence (Polit and Beck 2008:20; 192).  
In this study the researcher compared HIV infected TB patients who were enrolled on IPT 
with those patients who did not take IPT for occurrence of TB disease.   
3.2.3. Case-control studies 
Case-control design is the simplest and most commonly used study design that involves 
and looks the relationship between a ―case‖ and a ―control‖ (Polit and Beck 2008: 190; 
712; Joubert and Ehrlich 2007:82-85; 313). The researches begin from the outcome or 
cases, could be disease, and backwardly looks the disparity in exposure. The exposure is 
occurred or started in the past and prior to disease onset.  Case-control studies help in 
describing and realizing the outcome of interest or cause of a disease, determining the 
effect of events or interventions and investigation of disease outbreaks (Joubert and 
Ehrlich 2007:82- 85; 226; 313; Bruce et al 2008:  257- 305). 
 
Case control study design was employed in this study to assess the impact of TB 
preventive therapy on TB incidence. In this study, HIV infected TB patients who were 
receiving TB preventive therapy selected from hospitals were named as cases, whereas, 
HIV infected TB patients without prior IPT exposure from the same hospital were taken as 
controls.  
3.3. STUDY POPULATION AND SAMPLE 
3.3.1. Study Population 
Study population is the total set of persons (or objects) having common characteristics 
from which the sample is essentially selected (Polit and Beck 2008: 727). Polit and Beck 
(2008:50; 289) population is refers to the aggregate or total members possess specific 
attributes which a researcher is interested in studying. The population may consist of 
events, places, objects, animals, or individuals (Burns & Grove 2005:342). 
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 In most researches, two populations are illustrated, the target population and the 
accessible population.  
The study population in this study consisted of all HIV infected TB patents aged 14 years 
and older in Addis Ababa followed up in the Zewditu and Yekatit 12 hospitals between 
January 2008 and December 2010.  
3.3.2. Inclusion and exclusion criteria’s 
3.3.2.1. Inclusion criteria 
Those HIV Infected TB patients who received Isoniazid therapy from January 2008 to 
December 2010 at Zewditu and Yekatit 12 hospital and were eligible to participate in the 
study. 
3.3.2.2. Exclusion criteria 
 HIV infected individuals who were on ART,  
 TB patients with no HIV diagnosis,  
 HIV infected persons with unknown IPT start and end date   
 HIV infected persons with prevalent TB diagnosis at the time of HIV diagnosis  
 Due to similarity of many HIV allied infections like Pneumocystis carinii pneumonia, 
viral and bacterial pneumonias, the study was limited to HIV Infected TB patients 
who are aged 14 and over.  
3.3.3. Sampling frame 
Polit and Beck (2008: 296; 731) and De Vos and colleagues (2007:194) describe sampling 
frame as a listing of the elements of the population from which the sample will be selected 
(Joubert and Ehrlich 2007: 94-95).  
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The sampling frame of this study was a list of HIV infected individuals who were diagnosed 
and/or followed up at Zewditu and Yekatit 12 hospitals in Addis Ababa between January 
2008 and December 2010 period.   
 
3.3.4. Study Area and Period 
This study was carried out at the capital city of Ethiopia, Addis Ababa. Addis Ababa is the 
most populous and chartered city of Ethiopia with a total population of 2.8 millions 
contributing 3.7% to the nation population (Federal democratic republic of Ethiopia: 
Population census Commission 2008:10). There are nine public hospitals serving people 
infected with HIV and co-infected persons in Addis Ababa.  
Zeweditu hospital and Yekatit 12 hospitals are the two general hospitals in Addis Ababa 
most used for TB/HIV treatment since 2008.  
The study was conducted from May to October 2012.   
 
3.3.6. Sampling 
Polit and Beck (2008: 291; 731) and De Vos and colleagues (2007:194) concurs that 
sampling is the way of choosing a section of the population who will be studied to 
represent the whole population (Joubert & Ehrlich 2007: 190; 94-105).  
This study reviewed a record of 489 HIV and TB infected patients.  Some were enrolled on 
IPT and others were not.   
3.3.6. Sample size 
The sample size was calculated by using two sample proportion formula using Epi-Info 
version 3.3 for windows. The calculation was based on the assumption of 0.05 alpha level, 
study power of 80%, 1: 2 case-to-control ratio and 2.0 desired OR level. The proportion of 
controls with exposure (IPT) was assumed 70% and 30% for cases. Using Epi-Info sample 
size calculator, 148 cases and 295 controls were estimated to give sample size of 443.  A 
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10% was added on this sample size to adjust for incomplete patient records. The final 
sample size became 489 (163 cases and 326 controls).  
The list of all HIV infected TB patients who received IPT or not, was extracted from the 
ART and TB entry and follow-up register. In order to get the required number of 
participants, the investigator used computer generated table of random numbers to take a 
sample of patient ID numbers from the register.  Simple random sampling is a technique in 
which elements are selected for the study in a random manner in-order to get 
representative sample (Joubert and Ehrlich 2007: 95-97). All the elements had the same 
possibility to being included for the case and control group. 
3.4. RESEARCH ASSISTANT 
At the beginning, discussion was made with the ART clinic heads for the selection of 
nurses who had an experience and training on ART/TB formats. Permission was given to 
use the nurses for data abstraction during off-duty days. The nurses worked in ART 
program and were familiar with TB/HIV and ART data collection forms. The nurses were 
well acquainted with the current knowledge of ART and TB infection and treatment 
guidelines and the current Ministry of Health ART/TB intake and follow-up forms. One day 
training was given for data abstractors before the start of data collection process. The 
principal investigator took the responsibility of quality assurance and quality control for the 
study.  
3.5. THE INSTRUMENT   
A questionnaire is a printed document with a list of questions designed to gain information 
on a certain variables (Joubert and Ehrlich 2007:106-116).  Similarly, Polit and Beck 
(2008:729; 236) argues that questionnaire is a technique of gathering information from 
participants using a list of questions in a written format.  
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A structured data collection checklist was developed containing closed-ended questions. 
The national ART and TB entry and follow up form, the national TB/HIV guideline and 
exiting literature on TB/HIV were the basis for the development of data abstraction tool 
used in the study. The TB/HIV collaborative activity and ART unit were consulted for 
review of the tool.  
The tool comprised of 6 sections, namely: 
      Section 1: Socio-demographic characteristics 
      Section 2: Baseline clinical, laboratory and treatment information 
      Section 3: Social condition of patients 
      Section 4: Health education, knowledge and risk behaviours 
      Section 5: Follow-up information 
      Section 6: Information on TB treatment outcome  
Before the actual data collection procedure took place, data collection checklist was piloted 
in Black Lion Hospital, which was in the same region as study areas, and suitable 
modifications were made afterwards.    
3.6. DATA COLLECTION 
Polit and Beck (2008:716) defines data collection as a methodical information gathering 
technique which helps assembling of appropriate information to the focus of study and 
applied to address a research problem.  
In this study, data was collected using data abstraction checklist. The checklist was piloted 
before the actual data collection procedure took place.  Piloting was used to identify gaps 
in the data collection instrument and correct formatting and TB/HIV variable related errors.  
Each HIV infected TB patient normally has uniquely identifiable ID number which appears 
on the ART/TB intake and follow-up cards. Each-day after the patient received medication 
and/or counselling services, data entry clerks transfer the updated information into an 
electronic database. 
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PLHIVs where were followed at pre-ART clinic, diagnosed with active TB and/or who 
received IPT during the period of January 2008 and December 2010 were identified and 
listed (using clinic IDs) and samples were drawn randomly. Patients with the selected ID 
numbers were identified, printed and passed over to hospital registrar, which was 
responsible to identify and provide data abstractors with the individual patient records.  
The data collectors were responsible to abstract data from patient records, while quality 
assurance and quality control was made by principal investigator.  
3.7. DATA ANALYSIS 
Collected quantitative data need analysis and interpretation with the intention to be able to 
answer the study questions and the testing of study assumption using those data. De Vos 
et al (2007:218) and Polit and Beck (2008:716) explain data analysis as is a systematic 
organization, classifying, manipulating and eventually summarizing and synthesis of study 
data. Data analyses give outline to the study, elicit meaning from research data and help in 
drawing conclusion about the study population (De Vos et al 2007:217-219; Polit and Beck 
2008: 716).  
The principal investigator assessed the abstracted data for completeness and carried out 
data cleaning and a statistician was consulted during data processing and analysis. Data 
was entered into SPSS version 16.0.  Data was described using graphs, tables, charts and 
diagrams and statistical associations were calculated using analytic tests including odds 
ratio and chi-square test.  
3.8. RELIABILITY AND VALIDITY 
3.8.1. Reliability  
Reliability helps to assess the quality and adequacy of quantitative instruments. Dyson and 
Brown (2006:112-128) and Polit and Beck (2008:43; 416-428) describe reliability shortly as 
the stability, repeatability and regularity of information obtained in a study.  
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It is important to ensure the reliability of the instrument. The ability of an instrument is 
considered reliable when it measures the target attribute consistently and accurately and 
provide the same result again and again (Dyson and Brown 2006:112- 128; Joubert and 
Ehrlich 2007: 116-122). 
To ensure the reliability of the instrument, current national ART/TB intake and follow-up 
forms were used to guide its development. Close-ended questions were used.  
Experienced TB and ART clinic staff were used as data abstractors. Data collection 
checklist was piloted to identify gaps in the tool and they were corrected before actual data 
collection.  
 
3.8.2. Validity   
Validity concerns the soundness and rationality of the study‘s evidence or it measures the 
ability of the data collection tool to measure what it is intended to measure (Polit  and Beck 
2008: 43; 416-428; Joubert and Ehrlich 2007: 116-122).  
 Joubert and Ehrlich (2007: 120-121) and Polit and Beck (2008:423) define face validity as 
the degree to which the measurement creates a sense to the interviewer or individuals 
who have understanding on the subject matter or those who are familiar with the language 
and culture. Whereas, content validity described as the extent to which instrument has a 
suitable contents for the subject being measured.  
 
The quality of data was, also, ensured starting from the development of appropriate data 
collection checklist up to the data entry and analysis process. The researcher used already 
existing ART and TB intake and follow-up format to develop the questionnaire which 
maintains the validity. Besides, In order to improve the validity of the study and instrument, 
the researcher defined terms and contextualized for the specific research. Furthermore, 
the instrument was developed to answer the study questions according to the research 
objectives and existing literatures.  
An extensive literature review was conducted in order to ascertain the content validity for 
data abstraction tool.  All formats were checked for completeness and uniformity to ensure 
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both the content and face validity. Pre-testing and continuous supervision maximized the 
quality of data.  
3.9. ETHICAL CONSIDERATIONS 
Polit and Beck (2008: 717) define ethics as ―a system of moral values that is concerned 
with the degree to which research procedures adhere to professional, legal, and social 
obligations to the study participants‖. Implementation of a research that violates the ethical 
principle is immoral and unethical. Though, this research purely uses secondary data from 
follow up and entry forms, the ethical protocol were strictly followed.    
3.9.1. Ethical Permission 
Before the start of data collection, the investigator was obtained ethical clearance from the 
Higher Degrees Committee of the Department of Health Studies of the University of South 
Africa (annexure A). Then, permission to undertake the study was achieved from the 
ethical committee of city government of Addis Ababa city council health bureau. The 
necessary information about the study was offered to the Addis Ababa city council health 
bureau, hospital officials and health personnel‘s in the ART clinic.  
3.9.2 Informed Consent 
During this retrospective study, the researcher had no direct contact with participants. 
Hence, there was no need to develop an informed consent. After securing ethical 
clearance from the health bureau, authorization letter was written from Addis Ababa City 
Administration Health Bureau to Zewditu and Yekatit 12 Hospital Managements. This 
helped to get permission to use the data from the hospitals. 
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3.9.3. Protecting the Right of the Participants 
3.9.3.1. Anonymity 
Anonymity is a way of protecting the privacy of study participants. The investigator cannot 
associate participants or individuals with the information offered in a study with maintained 
its anonymity (Polit and Beck 2008: 149; 711; Joubert and Ehrlich 2007:32).  
No personal identification (ID) of individual patient (name, address and telephone 
numbers, etc.) was collected rather anonymous ART identification numbers were used. 
The information collected form participants were not linked to either the participants or the 
institution. The researcher followed the same principle while reports and findings were 
published.  
3.9.3.2. Confidentiality 
Polit and Beck (2008:714) explain confidentiality as protecting the privacy of prospective 
participants in a study. Therefore, the information that is collected is not allied with 
individuals participating in the study and by no means publicly disclosed. This study 
employed a retrospective institution based record review and all information was collected 
in protected and confidential way. 
 
 ART nurses working at TB/HIV clinics were recruited for data abstraction and supervision.  
This guaranteed confidentiality of patient data because that is part and parcel of their daily 
responsibility. Besides, no third person had access to the data other than the study team.  
Computers used for data analysis were password protected. 
3.9.3.3. Beneficence 
Beneficence imposes the researcher to reduce harm and maximize benefits on the study 
participants (Polit and Beck 2008:170). The result of the study gave highlight about IPT 
effectiveness in the prevention of tuberculosis. The result may encourage expansion of the 
service at all level and improve the attitude of practitioners that will improve the utilization 
of INH prophylaxis by the participants; thus, the participants will have better quality of life.  
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The findings of this study would help in providing information on program implementation 
and its challenges for health planners and managers to strengthen and expand IPT 
services at all facility level. This indirectly may help HIV infected individuals to have access 
to and utilization of TB prophylaxis at health facilities of their vicinity.  
3.9.3.4. Non-maleficience  
Non-maleficience inculcates the investigator not to harm others deliberately (Joubert and 
Ehrlich 2007:33). Since the study didn‘t involve clinical trial, no potential harm or risks were 
foreseen. The researcher utilized neither direct contact with the participants nor any kind of 
procedures during the conducting the study. Therefore, the study had no emotional, social 
or physical harm to the participants. 
3.9.4. Protecting the Rights of the Institution 
The proposal was submitted to the research and ethical committee of the University of 
South Africa for ethical clearance.  Then permission to collect data was sought from Addis 
Ababa health bureau and medical directors of the hospitals. All facet of the research was 
disclosed to the health bureau, the management of the hospital and then to the ART clinic 
head and staffs. Discussion on the objective and methodology was made with Addis 
Ababa Health bureau ethical clearance committee, hospital disease prevention and control 
core process owner and ART nurse data collectors. No information was given to third party 
without the permission of Addis Ababa Health bureau and the Hospital. Permission will be 
requested form Addis Ababa Health Bureau to publish the research finding. 
3.9.5. Human right 
This research employed a retrospective institution based record review and all information 
was collected in protected and confidential way. Merely, ART nurses were recruited for 
data collection and supervision, this guaranteed confidentiality. Besides, no third person 
had access for the data without the permission of the hospital or health bureau.   
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3.10. SUMMARY   
The chapter dealt with research methodology incorporating the research design, study 
population, sample, the instrument and researcher/data collector, data collection and 
analysis and ethical standards that directed the study. Data was collected from HIV 
infected TB patients who were on IPT and those HIV infected TB patients who were under 
follow up between January 2008 to December 2010 at Zewditu and Yekatit 12 hospital.  
 
In the next chapter, the results of the study will be presented. 
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CHAPTER 4 
ANALYSIS AND INTERPRETATION 
 
4.1. INTRODUCTION 
This chapter included the overall research findings and presented as data analysis and 
interpretation, including discussion of study findings and their programmatic implications. 
 
The specific objectives for this study were to: 
 To compare  the incidence of TB among HIV infected clients who received IPT and 
those who did not 
 To determine the socio-demographic and behavioural factors associated with TB 
incidence among HIV infected patients. 
 To compare HIV disease related factors associated with TB infection among those 
who received IPT and those who did not 
 
The tool was divided into six sub-sections, while, in-order to answer the study objectives 
the data was analysed including the following sections: 
Section 1: Socio-demographic and social characteristics 
Section 2: Social factors 
Section 2: Baseline clinical and laboratory information 
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4.2. DATA MANAGEMENT AND ANALYSIS 
The sample size consisted of 489 HIV patients co-infected with TB: 163 were receiving 
INH prophylaxis and the remaining 326 were not. Data was abstracted from registers by 
trained nurses who had experience working in TB and HIV. Quality of data was monitored 
by supervisors and the principal invigilator. Data was entered and analysed using SPSS 
for windows version 16. 
4.3. RESULTS 
The following sections discuss data analysis in the context of the study‘s research 
objectives and to answer the question according to the order in the questionnaire. 
4.3.1. Socio-demographic Characteristics 
The socio-demographic factors included age, sex, and marital status, level of education, 
and religion. 
4.3.1.1 Sex 
A total of 489 patient records were reviewed and majority were females 285 (58.3%).  
Among those who were receiving IPT, 49 (30.1%) were males and 114 (69.9%) were 
females (OR=2.11; 95% CI 1.42, 3.14). Among the 326 patients who didn‘t take IPT, 155 
(47.5%) patients were males (Table 4.1) 
4.3.1.2 Age 
The mean age of patients who were on IPT was 33.76 years with a standard deviation 
(SD) of 8.20.  It was 37.31 years (SD=8.45) for those who were not receiving INH 
prophylaxis (OR=0.048; 95% CI 0.004, 0.52). Those who developed tuberculosis and who 
were not on INH were on average 4 years older than those who were on IPT (p<0.001) 
(Table 4.1).  
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4.3.1.3 Marital Status 
About 50% of both patient groups (those receiving INH prophylaxis and those who did not) 
were living in marital union.  A quarter of patients receiving INH prophylaxis were never 
married compared to a fifth of those who did not.  There was no statistically significant 
difference between the two groups regarding marital status (Table 4.1).   
4.3.1.4 Educational status 
About 40% of both groups had secondary education, and less than a quarter of them went 
to tertiary level education.  There was no statistically significant difference in educational 
status between those who were receiving IPT and those who did not (Table 4.1). 
4.3.1.5 Religion 
Of the overall study participants, 80.4% were followers of Orthodox Christianity.   
Protestant Christians and Muslims constituted 11.7% and 6.1% respectively.  There was 
no statistically significant difference between those who were taking INH and those who 
did not with regards to religion (Table 4.1). 
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Table 4.1: Socio-demographic characteristics of patients, Addis Ababa, Ethiopia (n=489)  
Variable INH Prophylaxis OR; 95% CI X2 (p value) 
Yes: 163(100%) No: 326(100%) 
Sex Male 
R
 49 (30.1%) 155 (47.5%) 1.0  
Female 114 (69.9%) 171 (52.5%) 2.11; (1.42, 3.14) 
Age  
 
 
 
<20 
R
 6 (3.7%) 1 (0.3%) 1.0  
 
X
2
= 26.37 
(p=0.001) 
20-24 10 (6.1 %) 9 (2.8 %) 0.19; (0.019, 1.85) 
25-34 
77(47.3 %) 115 (35.3 %) 
0.11;  (0.013, 
0.95) 
35-44 52 (31.9 %) 138 (42.3 %) 0.06; (0.007, 0.54) 
45-54 
18 (11 %) 63(19.3 %) 0.05; (0.005, 0.42) 
Marital Status  
 
Never Married 
R
 46 (28.2%) 66 (20.2%) 1.0  
 
X
2
= 10.86 
(p=0.028) 
Married 82 (50.3%) 165 (50.6%) 2.09; (1.03,  4.26) 
Separated 8 (4.9%) 7 (2.1%) 1.49; ( 0.77, 2.89) 
Divorced 13 (8.0%) 46 (14.1%) 3.43; (1.05, 11.17) 
Widowed 14 (8.6%) 42 (12.9%) 0.85; (0.36, 2.01) 
Educational 
status  
No education 
R
 14 (8.6%) 26 (8.0%) 1.0  
 
X
2
= 6.48 
(p=0.09) 
Primary 45 (27.6%) 109 (33.4%) 0.77; (0.37,  1.60) 
Secondary 63 (38.7%) 139 (42.6%) 0.84; (0.41, 1.72) 
Tertiary 41 (25.2%) 52 (16.0%) 1.46; (0.68,, 3.16) 
Religion  Orthodox
 R
 133 (81.6%) 260 (79.8%) 1.0  
 
X
2
=1.01 
(p=0.798) 
Protestant 17 (10.4%) 40 (12.3%) 0.84; (0.37, 1.88) 
Muslim 9 (5.5%) 21 (6.4%) 0.83; (0.45, 1.52) 
Catholic 4 (2.5%) 5 (1.5%) 1.56; (0.41, 5.92) 
Occupational 
status   
Jobless
 R
 78 (47.9%) 129 (39.6%) 1.0  
 
X
2 
= 16.08 
(p=0.007) 
Go'vtal 
Employee 
49 (30.1%) 78 (23.9%) 1.04;  (0.66, 1.64) 
Day Labourer 20 (12.3%) 82 (25.2%) 0.40; (0.23, 0.71) 
Merchant 16 (9.8%) 29 (8.9%) 0.91; (0.47, 1.79) 
                              R: stands for reference variable  
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4.3.1.6 Occupational status 
Occupation wise, 42.3% (207/489) of the patients were jobless 26% were employee of 
governmental organizations and 20.9% were daily labourers (Table 4.1).   
4.3.2 SOCIAL FACTORS 
4.3.2.1. Living Home 
Table 4.2: Number of living rooms and number of people per household, Addis 
Ababa,Ethiopia 2012 (n=489) 
Variable INH Prophylaxis OR; (95% CI) X
2 (
p value) 
Yes: 163(100%) No: 326(100%) 
 
Number of 
rooms 
1-3
R
 134 (82.2%) 288 (88.3%) 1.0  
X
2
= 8.06 (p=0.045) 4-6 
25 (15.3%) 29 (8.9%) 
1.96; ( 1.10,  
3.49) 
7-9 
4 (2.5%) 4 (1.2%) 
2.46; ( 0.60, 
10.20 ) 
>10 0 (0%) 5 (1.5%) 0.00; ( 0.00, 0.00) 
 
 
People per 
room 
1-3
R
 127 (77.9%) 229 (70.2%) 1  
X
2
= 4.96 (p=0.18) 4-6 34 (20.9%) 84 (25.8%) 0.68; (0.43, 1.09) 
7-9 2 (1.2%) 10 (3.1%) 0.34; (0.07, 1.59) 
>10 0 (0%) 3 (0.9%) 0.84; (0.00, 1.34) 
                                     R: Stands for reference category 
Out of the 489 patients, 422 (86.3%)  were living in houses which had rooms ranging from 
1 to 3 and only five (0.2%) individual had living rooms greater or equal to ten rooms. Of 
those who lived in house with 1-3 rooms, 134 (81.6%) were provided IPT and 288 (88.9%) 
were non IPT groups (Table 4.2).  
Regarding number of people per room, 356 (72.8%) patients were living in rooms shared 
by up to three other individuals. About a quarter of them (118) had 1 to 3 rooms and the 
numbers of people living in these rooms were range from 4 to 6 (Table 4.2).  There was no 
statistically significant difference in the number of peoples living in a room between those 
who were enrolled on IPT and those who did not (Table 4.2). 
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4.3.3. BASELINE CLINICAL AND LABORATORY FACTORS 
4.3.1.1 Tuberculosis incidence 
Among those who were receiving Isoniazid, 23 (13.6%) developed tuberculosis while on 
INH therapy. Out of 326 participants who were not on INH, 225 (69.2%) of them had 
confirmed tuberculosis. The analysis revealed that the TB incidence rate among those who 
developed TB after completing isoniazid was significantly lesser when compared to those 
who were not on isoniazid (OR= 0.072; 95% CI 0.044, 0.12) (table 4.3). This association 
persisted even after controlling for confounders using logistic regression analysis 
(AOR=12.1; 95% CI 4.54, 32.02). 
Table 4.3:  Tuberculosis incidence among INH and Non-INH groups in Addis Ababa, 
Ethiopia 2012 (n=489) 
 
 
INH prophylaxis 
 
 TB No TB Total OR (95% CI) 
YES 23 (14.1%) 140 (85.9%) 163  
OR= 0.072;  (95% CI 0.044, 
0.12) 
NO 225 (69.0%) 101 (31.0%) 326 
TOTAL 248 (50.7%) 241 (49.3%) 489 
 
4.3.3.4. CD4 Result 
The figure below (Figure 4.1) shows the level of CD4 count during HIV diagnosis among 
TB co-infected HIV patients who were on INH and compared with those who were not. 
Less than one-third (7 out of 23) of those who developed TB while taking INH and more 
than ninety percent (209 out of 225) of those who didn‘t receive INH had CD4 count less 
than 350 cells per μL at HIV diagnosis. Having CD4 count less than 350 cells per μL at 
diagnosis of HIV was strongly associated with the group who was not put on INH 
prophylaxis and hence were at more risk of TB infection ( OR = 0.02;  95% CI 0.006, 
0.065).  
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Figure 4.1: CD4 count at HIV diagnosis among patients who developed TB infection while  on INH 
prophylaxis and those not on INH, Addis Ababa, Ethiopia 2012. 
 
The percentage of TB infected patients with CD4 counts < 350 cells per μL at HIV 
diagnosis reduced by 38.3% during the six months of follow up period among those who 
were not put on INH (Figure 4.2).  
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Figure 4.2: CD4 count of INH and Non-INH groups after six months of follow-up in Addis Ababa, Ethiopia 
2012. 
4.3.3.3. WHO clinical stage of patients 
Concerning the WHO clinical staging of HIV/AIDS disease, more than half (52.9%) of 
those who developed tuberculosis and about two-fifth of patients who were on INH had 
stage four clinical staging at HIV diagnosis (Figure 4.3; Figure 4.4).  
None of patients who developed TB infection while on INH prophylaxis were in WHO 
clinical stage 4 at the time of HIV diagnosis compared to 52.9% of those who developed 
TB infection and were not put on INH prophylaxis (OR 3.01; 95% CI 1.44, 6.25).     
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Figure 4.3: WHO clinical staging during HIV diagnosis among tuberculosis co-infected patients who were on 
INH in Addis Ababa, Ethiopia 2012  
The analysis on entry clinical stage showed that, almost equal proportions (44%) of those 
who developed tuberculosis while receiving isoniazid and those who did not were 
categorized at stage three.  Only six patients among those who were not enrolled on INH 
therapy and four from co-infected patients who were on INH were categorized either in 
stage one or two (Figure 4.3; Figure 4.4).   
Patients who developed TB without receiving INH had higher odds of being at advanced 
stage of HIV infection than those who developed TB while receiving INH (OR=0.24; 95% 
CI 0.075, 0.78).  
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Figure 4.4: WHO clinical stage at HIV diagnosis among TB co-infected patients who were not on INH in 
Addis Ababa, Ethiopia 2012 
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4.3.3.4. ASSOCIATED FACTORS  
Table 4.4: Association of tuberculosis infection with socio-demographic, TB/HIV/AIDS 
outcomes and behavioural factors in Addis Ababa, Ethiopia 2012 (n=489) 
Variable OR; (95% CI) X
2 
 p value AOR; (95% CI)  
Socio-demographic Factors 
     Age 0.046; (0.003, 0.51)*  26.3  0.001 0.14; (0.03, 0.97)* 
     Sex 2.08; (1.39, 3.13)* - - 1.86; (1.02, 2.23)* 
     Marital Status
+
 1.0 - - 1.0 
     Educational status 0.98; (0.46, 2.07) 5.86  0.12 0.93; (0.73, 1.17)  
     Religion 3.74; (0.77, 18.23) 3.97  0.27 0.88; (0.68, 1.13) 
    Occupation 1.01; (0.062, 16.36) 1.21  0.94 1.04; (0.86, 1.25) 
TB/HIV/AIDS outcome Related factors 
  CD4 result      
     During HIV diagnosis 0.18; (0.12, 0.29)* - - 0.21; (0.13, 0.31)* 
     After 6 months 1.18 (0.83, 1.69) - - 0.99; (0.67, 1.46) 
   WHO clinical staging 0.104; (0.023, 0.47)* 14.69  0.002 1.22; (1.09, 1.84)* 
   Previous History of TB 2.31; (1.44, 5.22) *  11.91 0.035 1.98; (1.20, 4.83)* 
   Previous TB Rx Outcome 1.09 (0.36, 3.14)  7.56 0.059 0.95 (0.20, 3.43)  
Behavioural Factors 
    Tobacco 1.00; (0.85, 1.19) 0.001 0.97 0.97; (0.80, 1.17) 
    Alcohol 0.73; (0.60, 0.90)* 9.50  0.002 0.82; (0.66, 1.01) 
    Soft Drugs 0.83; (0.70, 0.98)* 4.73  0.03 0.90; (0.75, 1.08) 
    Hard Drugs 1.13; (0.83, 1.55) 0.60 0.44 1.16; (0.83, 1.61) 
Social Factors  
Peoples per room 1.06; (0.67, 1.69) 1.50 0.68 2.12; ( 0.79, 4.90)  
* show the presence of association; 
+ 
indicates the reference and comparison variable 
As shown in table 4.4, age (OR= 0.046; 95% CI 0.003, 0.51) and sex (OR=2.08; 95% CI 
1.39, 3.13) had significant association with tuberculosis incidence. Both age (AOR= 0.14; 
95% CI 0.03, 0.97) and sex (AOR= 1.86; 95% CI 1.02, 2.23) remained statistically 
significant during multivariate analysis.     
CD4 count at HIV diagnosis (OR= 0.18; 95% CI 0.12, 0.29) and WHO clinical staging (OR 
0.104; 95% CI 0.023, 0.47) were also associated with incidence of tuberculosis.  Both CD4 
count during HIV diagnosis (AOR= 0.21; 95% CI 0.13, 0.31) and WHO clinical staging 
(AOR= 1.22; 95% CI 1.09, 1.84) remained significantly associated with TB incidence at 
multivariate analysis.   
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Pervious history of tuberculosis (OR= 2.31; 95% CI 1.44, 5.22) was significantly 
associated with tuberculosis incidence. This significance also continued in controlled 
analysis with a P value of 0.035. However, previous tuberculosis treatment outcome (OR= 
1.09; 95% CI 0.36, 3.14) was not significantly associated with tuberculosis infection (p= 
0.059).  
Among the behavioural risk factors, alcohol (OR= 0.73; 95% CI 0.60, 0.90) and use of 
stimulant drugs (e.g. Khat, Shisha...etc) (OR= 0.83; 95% CI 0.70, 0.98) were associated 
with incidence of tuberculosis on the bivariate analysis. But, in controlled multivariate 
analysis, this association remained statistically insignificant. 
In general, age (AOR= 0.14; 95% CI 0.03, 0.97) and sex (AOR= 1.86; 95% CI 1.02, 2.23) 
of the patient, CD4 count at HIV diagnosis (AOR= 0.21; 95% CI 0.13, 0.31), WHO clinical 
stage at HIV diagnosis (AOR= 1.22; 95% CI 1.09, 1.84) and previous history of 
tuberculosis (AOR = 1.97; 95% CI 1.24, 3.67) were the major factors associated with 
tuberculosis incidence. 
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Table 4.5: Association of tuberculosis infection with socio-demographic, TB/HIV/AIDS 
outcomes and behavioural factors of Non-INH group, Addis Ababa, Ethiopia 2012 (n-489) 
 
Variable OR; (95% CI) X
2 
 p value AOR; (95% CI)  
Socio-demographic Factors 
     Age 0.26; (0.08, 0.93)*  13.72  0.034 0.69; (0.31, 0.92)* 
     Sex 0.57; (0.13, 0.99)* - - 2.01; (1.23, 4.46)* 
     Marital Status 
+
 1.0 - - 1.0  
     Educational status 0.16; (0.06, 0.54) * 22.83  0.0021 1.93; (1.43, 3.76)*  
     Religion 18.25; (1.41, 35.75) 3.81  0.14 0.81; (0.59, 1.11) 
    Occupation 0.16; (0.02, 0.74) * 8.88  0.035 2.25; (1.41, 3.60)* 
TB/HIV/AIDS outcome Related factors 
  CD4 result      
     During HIV diagnosis 0.22; (0.081, 0.73)* - - 1.92; (1.18, 6.71)* 
     After 6 months 1.21 (0.69, 2.11) - - 0.78; (0.48, 1.28) 
   WHO clinical staging 0.10; (0.04, 0.88)* 10.73  0.011 1.91; (1.11, 5.29)* 
   Previous History of TB 2.11; (1.89, 3.72)* 13.22 0.004 2.50; (2.00, 4.08)* 
   Previous TB Rx Outcome 0.94; (0.43; 2.97) 4.31 0.32 1.08; (0.86, 3.31) 
Behavioural Factors 
    Tobacco 0.35; (0.084, 3.26) 0.77 0.54 1.04; (0.83, 1.30) 
    Alcohol 0.38; (0.09, 0.79)* 7.08  0.048 0.83; (0.64, 1.07) 
    Soft Drugs 0.17; (0.097, 0.62)* 9.00  0.0021 0.96; (0.56, 1.21) 
    Hard Drugs 1.16; (0.23, 5.36) 1.07 0.69 1.28; (0.86, 2.61) 
Social Factors  
Peoples per room 2.12; (0.92; 5.11) 5.89 0.67 1.37; (0.76, 1.93) 
      * show the presence of association; 
+ 
indicate the reference and comparison variable  
 
The bivariate and multivariate analysis done to determine HIV disease related factors 
associated with TB infection among those who did not received IPT showed that age, sex, 
educational and occupational status from socio-demographic variables, and CD4 result 
during HIV diagnosis and WHO clinical staging from HIV/AIDS related factors had an 
association with tuberculosis infection among non-INH HIV infected tuberculosis patients. 
The bivariate analysis of socio-demographic variables showed that age (OR=0.26; 95%CI 
0.08, 0.93), sex (OR=0.57; 95% CI 0.13, 0.99), educational status (OR=0.16; 95%CI 0.06, 
0.54) and occupation (OR=0.16; 95%CI 0.02, 0.74) were shown to be statistically 
significant with tuberculosis infection among non-INH receiving HIV infected tuberculosis 
patients.  
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The multivariate analysis showed that the age, sex, educational and occupational status 
variables remained statistically significant (AOR=0.69; 95% CI 0.31, 0.92), (AOR=2.01; 
95% CI 1.23, 4.46), (AOR=1.93; 95% CI 1.43, 3.76), (AOR= 2.25; 95% CI 1.41, 3.60) 
respectively.  (Table 4.5)  
 
In the bivariate analysis, CD4 result during HIV diagnosis (OR=0.22; 95% CI 0.081, 0.73) 
and WHO clinical staging (OR= 0.10; 95% CI 0.04, 0.88) were also significantly associated 
with tuberculosis infection among HIV infected tuberculosis infection. After controlling for 
possible confounders by multivariate analysis this association continued to be significant 
(AOR=1.92; 95% CI 1.18, 6.71) and (AOR= 1.91; 95% CI 1.11, 5.29) accordingly. (Table 
4.5) 
 
As shown in Table 4.5, previous history of tuberculosis was shown to be significantly 
associated with tuberculosis incidence (OR= 2.11; 95% CI 1.89, 3.72). Nevertheless, 
previous tuberculosis treatment outcome was not significantly associated with tuberculosis 
infection among TB patients who were not put on INH (OR= 0.94; 95% CI 0.43, 2.97). 
(Table 4.5)  
 
The analysis of behavioural factors showed that alcohol (OR= 0.38; 95% CI 0.09, 0.79) 
and using soft drugs (OR= 0.17; 95% CI 0.097, 0.62) was shown to be statistically 
significant with tuberculosis infection. However, the multivariate analysis done with 
controlling for other variables this association was found to be insignificant (AOR= 0.83; 
95% CI 0.64, 1.07), (AOR= 0.96; 95% CI 0.56, 1.21) correspondingly. (Table 4.5) 
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Table 4.6: Association of tuberculosis infection with socio-demographic, HIV/AIDS 
outcomes and behavioural factors among INH group in Addis Ababa, Ethiopia 2012 
(n=489) 
 
Variable OR; (95% CI) X
2 
 F test AOR; (95% CI)  
Socio-demographic Factors 
     Age 0.25; (0.01, 0.91)*  9.19 0.0025 1.21; (1.01,3.46)* 
     Sex 7.28; (1.50, 35.54)*  0.0003 0.24; (0.08, 0.71)* 
     Marital Status+ 1.0 - - 1.0  
     Educational status 3.22; (0.08, 26.97)  2.91  0.67 1.01; (0.56,1.83) 
     Religion 0.063; (0.003,1.53) 1.16  0.09 0.86; (0.42, 1.77) 
    Occupation 1.40; (0.16, 12.30)  2.94  0.081 0.98; (0.60, 1.59) 
HIV/AIDS outcome related factors 
  CD4 result      
     During HIV diagnosis 0.25; (0.08, 0.78)* - 0.046 0.30; (0.12,0.97)* 
     After 6 months 0.71; (0.18, 2.85) - 0.54 1.23; (0.46, 3.27) 
   WHO clinical staging 0.14; (0.003, 0.68)* 14.09  0.011 1.51; (1.02, 2.29)* 
   Previous History of TB 2.62; (1.27, 5.93)* 8.61 0.0069 2.12; (1.09, 4.99)* 
   Previous TB Rx Outcome 0.56; (0.12; 2.74) 6.98 0.39 0.87; ( 0.41, 1.78) 
Behavioural Factors 
    Tobacco 2.46; (0.028, 37.18) 0.86 0.53 0.96; (0.55, 1.70) 
    Alcohol 2.15; (0.22, 20.89)   0.048 0.97; (0.53, 1.77) 
    Soft Drugs 2.02; (0.27, 15.07) 1.78 0.21 1.07; (0.69, 1.67) 
    Hard Drugs 1.62; (0.58, 4.53) 0.67 0.58 0.61; (0.12, 3.03) 
Social Factors 
Peoples per room 1.24; (0.26, 6.52) 7.21 0.86 0.89; (0.60, 1.79) 
           * show the presence of association; + show reference and comparison variable 
 
The bivariate analysis of socio-demographic variables, age (OR= 0.25; 95% CI 0.01, 0.91) 
and sex (OR= 7.28; 95% CI 1.50, 35.54) were associated with tuberculosis infection 
among HIV infected patients who received INH. The association between tuberculosis 
infection and socio-demographic variables, age and sex, was found to be significantly 
associated at p<0.005 and p<0.001 respectively. (Table 4.6)  
 
Regarding HIV/AIDS outcome related factors, CD4 result during HIV diagnosis with an OR 
0.25; 95% CI (0.08 to 0.78) and WHO clinical HIV/AIDS staging with an odds of 0.14; 95% 
CI (0.003 to 0.68) was significantly associated with tuberculosis infection.  
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Similarly, CD4 result during HIV diagnosis (p<0.05) and WHO clinical staging of patients 
(p<0.05) was statistically associated with tuberculosis infection of INH receiving HIV 
infected patients. (Table 4.6)     
 
As shown in table 4.6, history of tuberculosis had a significant association with tuberculosis 
incidence (p<0.05). However, previous TB treatment outcome, behavioural factors 
including tobacco smoking, alcohol and use of soft and hard drugs did not show significant 
association with tuberculosis infection among HIV infected patients who were receiving 
INH.  
 
4.4. SUMMARY 
This chapter presented the research findings as data analysis and interpretation. The 
study revealed that patients who were put on INH prophylaxis had lower chances of 
developing tuberculosis than patients who were not receiving INH prophylaxis. Sex and 
age, CD4 count at HIV diagnosis, WHO clinical staging and previous history of 
tuberculosis were significantly associated with tuberculosis incidence in both groups of 
patients. 
 
Bivariate and multivariate analysis conducted in the absence of INH prophylaxis among 
HIV infected patients showed that in addition to the aforementioned four variables 
educational and occupational status had also a significant role in tuberculosis incidence.   
However, the factors associated with tuberculosis infection among those who received 
isoniazid was similar to the overall listed variables.    
The next chapter will talk about these findings and conclusions and make 
recommendations based on these findings. 
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CHAPTER 5 
DISCUSSION, CONCLUSIONS AND RECOMMENDATIONS 
 
5.1. INTRODUCTION  
 
Chapter five presents the discussion, conclusion and recommendations part of the study 
made by the researcher. The discussion section will largely focus on interpretation of the 
research findings by considering the research objectives. Besides, it will compare and 
contrast the research findings with existing literatures.  
5.2. DISCUSSION OF FINDINGS 
The researcher set out three specific objectives for this specific study. The objectives 
compared the incidence of TB among HIV infected clients who received IPT and those 
who did not, determined the socio-demographic and behavioural factors associated with 
TB incidence among HIV infected patients and compared HIV disease related factors 
associated with TB infection among those who received IPT and those who did not. The 
outline of the discussion section follows these objectives. Recommendations were made 
on issues of key concern based on the study findings.  
The key finding of this study is the fact that tuberculosis incidence among those who 
received isoniazid prophylaxis was much lesser than those who didn‘t receive Isonizide 
therapy.  A prospective cohort done in South Africa found that HIV infected adults who 
were not under INH therapy had a higher degree of tuberculosis incidence than those who 
were receiving INH, which was similar to the present study finding (Golub et al 2009:631; 
634).  
This study showed that INH prophylaxis reduced tuberculosis risk by 0.07 (by almost 40%) 
which was comparable to the study done in Rio de Janeiro, Brazil (Golub et al 2007:1).  
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 A study done by Frigati and colleagues proved that those HIV infected persons who didn‘t 
enrol on INH had a greater tuberculosis incidence when compared to those who received 
the INH therapy which was similar to our finding (Frigati, Kranzer, Cotton, Schaaf, 
Lombard and Zar 2011:498-499 ). This finding also compares with a study result from 
South Africa (33%) (Charalambous et al 2010: S6). But lower than studies conducted in 
Rio de Janeiro, Brazil (70-90%) and a study by Padmapriyadarsini and colleagues which 
showed 67% overall reduction (Golub et al 2007: 1441; Padmapriyadarsini et al 2011: 
854).  
Age, sex, CD4 count at the time of HIV diagnosis, WHO clinical staging and previous 
history of tuberculosis were important socio-demographic and behavioural factors 
associated with TB incidence among HIV infected individuals.  Similarly, a study done 
among HIV infected individuals in Denmark identified that age, sex and CD4 count at HIV 
diagnosis were risk factors associated with tuberculosis (Taarnhøj et al 2011: 3-7). A study 
by Nicholas et al (2011: 313-315) also found sex, CD4 count and clinical staging to have 
significant association with tuberculosis risk.  
In this study, young HIV infected patients had a greater chance to be infected by 
tuberculosis than those who were at older stage. This finding is similar to a study done 
among Danish HIV patients which found patients at the lower age category to have greater 
risk for tuberculosis (p<0.036) (Taarnhøj, Engsig, Ravn, Johansen, Larsen, Røge, 
Andersen and Obel 2011: 3-7). 
HIV infected female patients who were on INH were more prone to develop tuberculosis 
than their male counterpart in our study. Similarly, a study done in Nigeria found 
statistically significant association between female by sex and tuberculosis infection 
(p=0<0.05).  
This study also found that majority of females who were receiving INH prophylaxis had 
higher CD4 count and less advanced WHO clinical stage. In contrast, among those who 
were not on INH, being female increased the risk of developing tuberculosis which was 
similar to study finding in South Africa (Komati et al 2011: 1851- 1853) and Nigerian study 
(Nicholas et al 2011: 313- 315).   
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Patients who had CD4 counts less than 350 cells per μL during HIV diagnosis had 78% 
more likely to develop tuberculosis than those who had CD4 counts greater than 350 cells 
per μL.  This finding was similar to a study done in Tanzania which showed that CD4 count 
depletion exacerbates the development of active tuberculosis. CD4 depletion, in turn, 
contributes to the worsening of clinical staging, which further contributes to the progression 
of severe forms of diseases (Andersen, Range, Changalucha, PrayGod, Kidola, Faurholt-
Jepsen, Krarup, Grewal and Friis 2012: 3-6; Taarnhøj et al 2011:3-7; Stephanus Komati, 
S, Shaw, PA, Stubbs, N, Mathibedi, MJ, Malan, L, Sangweni, P, Metcalf, JA, Masur, H and 
Hassim, S 2011: 1851- 1853).  
A multicohort study done in eight sub-Saharan African countries found that those 
individuals who had higher CD4 counts were less (30%) likely to develop tuberculosis than 
those who had lower counts (Nicholas, Sabapathy, Ferreyra, Varaine and Pujades-
Rodr´ıguez 2011: 313-315). Furthermore, the by Taarnhøj and colleagues in Denmark  
cited above showed that lower CD4 count at HIV diagnosis was associated with increased 
risk of tuberculosis infection (Taarnhøj et al 2011: 3-7).  
Clinical stage was identified as one of the risk factors for tuberculosis in this study. Being 
at WHO clinical stage four was positively associated with tuberculosis incidence when 
compared to those who were at other stages, this finding was comparable to study in Dar 
es Salaam, Tanzania (Ngowi, Mfinanga, Bruun and Morkve  2008: 1-7). Ngowi et al (2008: 
3-5) identified clinical stage as risk factor and as the clinical stage increases the risk of 
tuberculosis infection also increases. Ngowi and colleagues (2008:3-5) found that the risk 
of tuberculosis among stage four HIV infected TB patients was 70 times more than those 
at stage one.  
This study found that history of tuberculosis and previous treatment outcome had 
significant association with tuberculosis infection.  
Those HIV infected TB patients who had previous history of tuberculosis had more chance 
of tuberculosis re-infection when compared to those who had no history. Komati et al 
(2011: 1851- 1853) found that previous history of tuberculosis was related with increased 
risk of tuberculosis, which was comparable to this study.   
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Educational and occupational status of the patient was factors associated with tuberculosis 
among those who were not on isoniazid therapy. There is a dearth of studies on risk 
factors of tuberculosis among HIV infected peoples who were not on INH. However, a 
study conducted in South-west Ethiopia found that educational and occupational status of 
HIV infected patients was independently associated (Taha, Deribew, Tessema, 
Assegid, Duchateau and Colebunders 2011: 131- 139). A nested case-control study in 
Hunan province, China, similarly found that a low level of educational status was 
significantly associated with development of tuberculosis in peoples living with HIV 
(Chen, Yang, Chen, Tan, Bai, Zhang, Liu, Li G 2010:151-154). 
5.3. CONCLUSION 
INH prophylaxis has long been recommended by WHO as cost-effective public health 
measure to prevent TB among HIV infected individuals. Likewise, other studies conducted 
in different parts of the world found that INH prophylaxis to be effective in reducing 
tuberculosis infection among HIV infected patients. Nonetheless, the implementation of 
INH preventive therapy has remained very low in most developing countries including 
Ethiopia.  The recent increase in the coverage of ART among PLHIV, which in itself results 
in significant reduction of TB incidence, has limited the potential target group of PLHIV who 
benefit from INH prophylaxis.  The debate among the scientific community and decision 
makers on the most effective use of isoniazid preventative therapy will therefore continue 
for some time to come.   
This study that age, sex, CD4 counts, clinical stage and previous history of the patient 
were associated with tuberculosis infection. This underlines the need regular screening of 
TB infection for all PLHIV and early initiation of ART particularly among those with lower 
CD4 counts and previous history of TB as per the national TB/HIV guideline.   
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5.4. RECOMMENDATION  
Based on the study findings, the researcher makes the following recommendations:  
4. Ministry of Health 
4.9. Development of appropriate and easily understandable IPT guidelines for Health 
Managers and health professionals. 
4.9. Conduct more prospective studies to identify PLHIV who will most benefit from INH 
prophylaxis. 
4.9. Conducting TB/HIV service utilization and implementation assessments at all 
stages of the health care system. 
4.9. Including IPT as an integral part of TB/HIV planning, reporting and monitoring and 
evaluation. 
4.9. Increasing access and availability of IPT medications at all stages of TB/HIV 
service provision facilities.  
 
5. Addis Ababa city council health bureau  
 Intensified health education on the risk of TB infection among PLHIV.   
 Widespread implementation of regular TB screening for all PLHIV at each clinical 
visit. 
 Encourage use of INH prophylaxis for all PLHIV who do not have active TB and are 
not yet eligible for ART initiation according to the national ART guideline. 
 Active TB/HIV integration at all levels to improve identification of TB infection among 
PLHIV and initiation of ART among TB patients receiving anti-TB treatment.  
 Regular and continues follow up of health facilities to assess the implementation of 
the guidelines. 
 
 PLHIV and family/community members 
 PLHIVs should take prescribed medication on time and correctly without 
discontinuation  
 Family and community members should help PLHIVs in taking prescribed Isoniazid 
medication.   
54 
 
REFERENCES 
Addis Ababa City Council Health Bureau. 2010. Addis Ababa City Council Health Bureau: 
2010 facial year health facilities report. Unpublished report. Addis Ababa.  
Africa Union. 2006. Update on tuberculosis control in Africa. Africa Union. From:  
www.auspecialsummitonatm.net/ SP/Ex.CL/ATM/4 (I).pdf (accessed 16 July 2012). 
Akolo, C, Adetifa, I, Shepperd, S and Volmink, J. 2010.  Treatment of latent tuberculosis 
infection in HIV infected persons. John Wiley & Sons, Ltd: Issue 1.               
Andersen, AB, Range, NS, Changalucha, J, PrayGod, G, Kidola, J, Faurholt-Jepsen, D, 
Krarup, H, Grewal, HMS and Friis, H. 2012. CD4 lymphocyte dynamics in Tanzanian 
pulmonary tuberculosis patients with and without HIV co-infection. BMC Infectious 
Diseases 12 (66): 1-7. 
Balcells, ME, Thomas, SL, Godfrey-Faussett, P and Grant, AD. 2006. IPT and Risk for 
Resistant Tuberculosis. Emerging Infectious Diseases12 (5):744-751.  
Chakaya, J, Getahun, H, Granich, R and Havlir, D. 2008. Confronting TB/HIV in the era of 
increasing anti-TB drug resistance. Journal of the International AIDS Society 11(6):1-6.  
Charalambous, S, Grant, AD, Innes, C, Hoffmann, CJ, Dowdeswell, R, Pienaar, J, 
Fielding, KL and Churchyard, GJ. 2010. Association of isoniazid preventive therapy with 
lower early mortality in individuals on antiretroviral therapy in a workplace programme. 
AIDS 24 (Suppl 5): S5 – S13.  
Chen, MS, Yang, HL, Chen, YF, Tan, HZ, Bai, LQ, Zhang, YH, Liu, J and Li, GP. 2010. A 
nested case-control study on the influencing factors of tuberculosis among people living 
with HIV/AIDS in Hunan province. NCBI 31(2):151-154.  
Cohen, T, Lipsitch, M, Walensky, RP and Murray, M. 2006. Beneficial and perverse effects 
of isoniazid preventive therapy for latent tuberculosis infection in HIV–tuberculosis co-
infected populations. PNAS 103 (18): 7042- 7049  
55 
 
Crampin, AC, Mwaungulua, JN, Mwaungulu, FD, Mwafulirwa, DT, Munthali, K, Floyd, S, 
Fine, PEM and Glynn, JR. 2010. Recurrent TB: relapse or reinfection? The effect of HIV in 
a general population cohort in Malawi. AIDS 24(3): 417- 426. 
Date, AA, Vitoria, M, Granich, R, Banda, M, Fox, MY and Gilks, C. 2010. Implementation 
of co-trimoxazole prophylaxis and isoniazid preventive therapy for people living with HIV. 
World Health Organization 88:253–259. 
Datiko, DG, Yassin, MA, Chekol, LT, Kabeto, LE and Lindtjørn, B. 2008. The rate of TB-
HIV co-infection depends on the prevalence of HIV infection in a community. BMC Public 
Health 8:266.  
De Vos, AS, Strydom, H, Fouche, CB and Delport, CSL. 2007. Research at grass roots. 
3rd edition. Pretoria: Van Schaik. 
Deribew, A, Tesfaye, M, Hailmichael, Y, Negussu, N, Daba, S, Wogi, A, Belachew, T, 
Apers, L and Colebunders, R. 2009. Tuberculosis and HIV co-infection: its impact on 
quality of life. BMC Public health 7:105. 
Eldred, LJ, Churchyard, G, Durovni, B, Godfrey-Faussett, P, Grant, AD, Getahun, H and 
Chaisson, RE. 2010. Isoniazid preventive therapy for HIV-infected people: evidence to 
support implementation. AIDS 24 (Suppl 5): S1-S3. 
Ethiopia Federal HIV/AIDS prevention and control office. 2009. Strategic plan for 
intensifying multi-sectoral HIV and AIDS response in Ethiopia II (SPM II). Addis Ababa, 
Ethiopia: FHAPCO.  
Ethiopia Federal HIV/AIDS prevention and control office. 2010. Report on progress 
towards implementation of the UN Declaration of Commitment on HIV/AIDS. Addis Ababa, 
Ethiopia: FHAPCO.  
Ethiopia Federal Ministry of Health.  2008. TB, leprosy and TB/HIV prevention and control 
program: manual. 4th edition. Addis Ababa, Ethiopia: MOH.  
56 
 
Ethiopia Federal Ministry of Health. 2007a. Guidelines for Management of opportunistic 
infections and Anti retroviral treatment in adolescents and adults in Ethiopia. Addis Ababa, 
Ethiopia: MOH.  
Ethiopia Federal Ministry of Health. 2007b. Guidelines for implementation of the 
antiretroviral therapy programme in Ethiopia. Addis Ababa, Ethiopia: MOH.  
Ethiopia Federal Ministry of Health. 2007c. Implementation Guideline for TB/HIV 
Collaborative Activities in Ethiopia. Addis Ababa, Ethiopia: MOH. 
Ethiopia Federal Ministry of Health. 2008. Health and health related indicators. Addis 
Ababa, Ethiopia: MOH.  
Gao, L, Zhou, F, Li, X and Jin, Q. 2010. HIV/TB Co-Infection in Mainland China: A Meta-
Analysis. PLoS ONE 5 (Issue 5): 1-6. 
Getahun, H, Granich, R, Sculier, D, Gunneberg, C, Blanc, L, Nunn, P and Raviglione, M. 
2010. Implementation of Isoniazid preventive therapy for people living with HIV worldwide: 
barriers and solutions. Journal of the International AIDS Society 24 (Suppl 5):S57–S65. 
Golub, JE, Pronyk, P, Mohapi, L, Thsabangu, N, Moshabela, M, Struthers, H, Gray, GE, 
McIntyre, JA, Chaisson, RE and Martinson, NA. 2009. Isoniazid preventive therapy, 
HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort 
Journal of the International AIDS Society 23(5):631–636. 
Golub, JE, Saraceni, V, Cavalcante, SC, Pacheco, AG, Moulton, LH, King, BS, Efron, A, 
Moore, RD, Chaisson, RE and Durovni, B. 2007. The impact of antiretroviral therapy and 
Isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de 
Janeiro, Brazil. Journal of the International AIDS Society 21 (11):1441-1448. 
Granich, R, Akolo, C, Gunneberg, C, Getahun, H, Williams, P and Williams, B. 2010. 
Prevention of Tuberculosis in People Living with HIV. Clinical Infectious Diseases 50 
(Suppl 3):S215–S222.  
57 
 
Grant, AD, Mngadi, KT, Halsema, CL, Luttig, MM, Fielding, KL and Churchyard, GJ. 2010. 
Adverse events with isoniazid preventive therapy: experience from a large trial. AIDS 24 
(Suppl 5): S29–S36. 
Gray, DM, Young, T, Cotton, M and Zar, H. 2009. Impact of tuberculosis preventive 
therapy on tuberculosis and mortality in HIV-infected children (Review). Cochrane 
Corporation 4: 1-17.   
Jerene, D, Naess, A and Lindtjorn, B. 2006. Antiretroviral therapy at a district hospital in 
Ethiopia prevents death and tuberculosis in a cohort of HIV patients. AIDS Research and 
Therapy 3(10): 1-8. 
Jerene, D. 2007. HIV antiretroviral therapy in Ethiopia: Overcoming implementation 
challenges.  PhD (Doctoral Degree of Philosophy) dissertation. University of Bergen, 
Norway.  
Joubert, G and Ehrlich, R (eds). 2007. Epidemiology: A research manual for South Africa. 
2nd edition, South Africa: Oxford University Press. 
Kassa, A, Jerene, D, Assefa, Y, Teka, A, Aseffa, A and Deribew, A. 2012. Evaluation of 
collaborative TB/HIV activities in a general hospital in Addis Ababa, Ethiopia. BMC 
Research Notes 5(67): 1-6.  
Kloos, H, Assefa, Y, Adugna, A, Mulatu, MS and HaileMariam, D. 2007.  Utilization of 
antiretroviral treatment in Ethiopia between February and December 2006: spatial, 
temporal, and demographic patterns. International Journal of Health Geographics 6: 45. 
Lawn, S. 2010. The challenge of the HIV-associated tuberculosis epidemic in sub-Saharan 
Africa: will antiretroviral therapy help? South African Centre for Epidemiological Modelling 
and Analysis (SACEMA): 1-3. 
Lester, R, Hamilton, R, Charalambous, S, Dwadwa, T, Chandler, C, Churchyard, GJ and 
Grant, AD. 2010. Barriers to implementation of isoniazid preventive therapy in HIV clinics: 
a qualitative study. Journal of the International AIDS Society 24(Suppl 5):S45-S48. 
58 
 
Marais, BJ, Zyl, S, Schaaf, HS, Aardt, M, Gie, RP and Beyers, N. 2006. Adherence to 
Isoniazid preventive chemotherapy: a prospective community based study. Arch Dis Child 
91:762- 765.  
Mindachew, M, Deribew, A, Tessema, F and Biadgilign, B. 2011. Predictors of adherence 
to isoniazid preventive therapy among HIV positive adults in Addis Ababa, Ethiopia. BMC 
Public Health 11 (916): 1-7. 
Mohamed, H. 2011. Assessing the Impact of the Directly Observed Treatment Short-
Course (DOTS) for the Control of Tuberculosis in DOTS-Recipient Countries: Cross-
National Evidence. Msc thesis. University of Calgary. Alberta. 
Moore, D, Liechty, C, Ekwaru, P, Were W, Mwima, G, Solberg, P, Rutherford, G and 
Mermin, J. 2007. Prevalence, incidence and mortality associated with tuberculosis in HIV-
infected patients initiating antiretroviral therapy in rural Uganda. AIDS 21 (6): 713-719. 
Mosimaneotsile, B, Mathoma, A, Chengeta, B, Nyirenda, S, Agizew, TB, Tedla, Z, 
Motsamai, OI, Kilmarx, PH, Wells, CD and Samandari, T. 2010. Isoniazid Tuberculosis 
Preventive Therapy in HIV-Infected Adults Accessing Antiretroviral Therapy: A Botswana 
Experience, 2004–2006. J Acquir Immune Defic Syndr 54(1): 71-77. 
Naidoo, K, Naidoo, K, Padayatchi, N, and Karim, QA. 2011. Review Article: HIV-
Associated Tuberculosis. Clinical and Developmental Immunology. Volume 2011. Hindawi 
Publishing Corporation. 
Ngowi, BJ, Mfinanga, SG, Bruun, JN and Morkve, O. 2008. Pulmonary tuberculosis among 
people living with HIV/AIDS attending care and treatment in rural northern Tanzania. BMC 
Public Health 8 (341): 1-7.  
Nicholas, S, Sabapathy, K, Ferreyra, C, Varaine, F and Pujades-Rodr´ıguez, M. 2011. 
Incidence of Tuberculosis in HIV-Infected Patients Before and After Starting Combined 
Antiretroviral Therapy in 8 Sub-Saharan African HIV Programs. J Acquir Immune Defic 
Syndr 57 (4):311–318.  
59 
 
Nieburg, P, Ramachandran, S and Hofler, K. 2008. U.S. Policy Options for Strengthening 
Coordination between Global HIV/AIDS and TB Programs: A Report of the CSIS Task 
Force on HIV/AIDS. Washington, DC: Centre for Strategic and International Studies press.  
Olugbue, VU and Onuoha, SC. 2012. Prevalence of HIV Infection among Tuberculosis 
(TB) patients in a TB/HAART-HAART referral centre in Nigeria. International Journal of 
Science and nature 3(1): 88-92. 
Padmapriyadarsini, C, Narendran, G and Swaminathan, S. 2011. Diagnosis & treatment of 
tuberculosis in HIV co-infected patients. Indian J Med Res 134: 850-865.  
Patel, K, Herna´n, MA, Williams, P, Williams, PL, Seeger, JD, McIntosh, K, Van Dyke, RB 
and Seage, GR. 2008. Long-Term Effectiveness of Highly Active Antiretroviral Therapy on 
the Survival of Children and Adolescents with HIV Infection: A 10-Year follow-Up Study. 
Infectious Diseases Society of America 46:507–515. 
Pawlowski, A, Jansson, M, Sköld, M, Rottenberg, ME and Källenius, G. 2012. Tuberculosis 
and HIV co-infection. PLoS Pathogens 8 (issue 2):1-7.  
Polit, DF and Beck, CT. 2008. Nursing research: principles and Methods. 7th Edition, 
China: Lippincott. 
Pontororing, GJ, Kenangalem, E, Lolong, DB, Waramori, G, Sandjaja, Tjitra, E, Price, RN, 
Kelly, PM, Anstey, NM and Ralph, AP. 2010. The burden and treatment of HIV in 
tuberculosis patients in Papua Province, Indonesia: a prospective observational study. 
BMC infectious diseases 10: 362. 
Roeger, WL, Feng, Z and Castillo-Chavez, C. 2009.  Modelling TB and HIV co-infections. 
Mathematical Biosciences and Engineering 6(4): 815–837.  
Samandari, T, Agizew, AB, Nyirenda, S, Tedla, Z, Sibanda, T, Shang, N, Mosimaneotsile, 
B, Motsamai, OI, Bozeman, L, Davis, MK, Talbot, EA, Moeti, TL, Moffat, HJ, Kilmarx, PH, 
Castro, KG and Wells, CD. 2010. 6-month versus 36-month isoniazid preventive treatment 
for tuberculosis in adults with HIV infection in Botswana: a randomized, double-blind, 
placebo-controlled trial. The lancet 377(issue number 9777): 1588 – 1598.  
60 
 
Smart, T. 2009. Continuous isoniazid preventive therapy (IPT) better at preventing TB than 
short course — but only in those with a positive tuberculin skin test (TST). HIV and AIDS 
Treatment in Practice (HATiP) 151: 2-6.   
Szakacs, TA, Wilson, D, Cameron, DW, Clark, M, Kocheleff, P, Muller, FJ and McCarthy, 
A. 2006. Adherence with isoniazid for prevention of tuberculosis among HIV-infected 
adults in South Africa. BMC Infectious Diseases 6(97):1-7. 
Taarnhøj, GA, Engsig, FN, Ravn, P, Johansen, IS, Larsen, CS, Røge, B, Andersen, AB 
and Obel, N. 2011. Incidence, risk factors and mortality of tuberculosis in Danish HIV 
patients 1995 2007.BMC Pulmonary Medicine 11(26): 1-6.  
Taha, M , Deribew,A,  Tessema, F, Assegid, S, Duchateau, L and Colebunders, R. 2011. 
Risk Factors of Active Tuberculosis in People Living with HIV/AIDS in Southwest Ethiopia: 
A Case Control Study. Ethiopian Journal of Health Sciences 21(2): 131- 139.  
World Health Organization. 2007. Treatment of TB: guideline for national programmers. 3rd 
edition. World Health Organization, Geneva. WHO press. 
World Health Organization. 2010a. Priority research questions for Tuberculosis and human 
immune deficiency (TB/HIV) in HIV prevalent and resource limited settings. World Health 
Organization, Geneva. WHO press. 
World Health Organization. 2010b. Global Tuberculosis control: World Health 
Organization, Geneva: WHO press.  
World Health Organization. 2010c. Treatment of TB: Guideline. 4th edition. World Health 
Organization, Geneva. WHO press. 
World Health Organization. 2011a. Guidelines  for  intensified  tuberculosis  case-finding  
and  isoniazid  preventive  therapy  for  people  living  with  HIV  in  resource-constrained 
settings. World Health Organization, Geneva: WHO press. 
World Health Organization. 2011b. Global Tuberculosis control 2011. World Health 
Organization, Geneva: WHO press.  
61 
 
World Health Organization. 2011c. World Health Statistics. World Health Organization, 
Geneva: WHO press.  
World Health Organization. 2012. Collaborative TB/HIV activities: Guidelines for national 
programmes and other stakeholders. World Health Organization, Geneva: WHO press. 
Zanoni, BC, Phungula, T, Zanoni, HM, France, H and Feeney, ME.  2011.  Impact of 
tuberculosis cotreatment on viral suppression rates among HIV-positive children initiating 
HAART. AIDS 25 (1): 49-55. 
Zar, HJ, Cotton, MF, Strauss, S, Karpakis, J, Hussey, G, Schaaf, HS, Rabie, H and 
Lombard, CJ. 2006. Effect of INH prophylaxis on mortality and incidence of tuberculosis in 
children with HIV: randomized control trial. BMJ: 1-7. 
 
 
 
 
 
 
 
 
 
 
62 
 
PERMISSION LETTER TO CONDUCT RESEARCH 
 
Sade, Anteneh Habtemariam 
Addis Ababa 
 
Addis Ababa City Administration counsel  
Health Bureau  
Addis Ababa 
 
RE: PERMISSION TO CONDUCT RESEARCH 
Dear Sir/Madam, 
I am a registered MPH student at the University of South Africa (UNISA) conducting study 
for the partial fulfilment of Masters Degree in public health. I secured the necessary ethical 
clearance from University of South Africa, Department of health studies ethical.  
The main purpose of the study is to measure the impact of Isoniazid preventive therapy on 
the incidence of tuberculosis among TB/HIV co-infected infected individuals at Zewiditu 
and Yekatit 12 hospitals in Addis Ababa, Ethiopia. The study requires secondary data on 
TB and HIV from January 2008 to December 2010 from ART clinic and TB Unit. 
It is my hope that the findings from this study will assist in understanding the impact of INH 
prophylaxis in the prevention of tuberculosis among HIV infected persons.  
I shall be very delighted if you can grant me the permission to carry out the study. If you 
have any queries or clarification, please do not hesitate to contact me. 
 
Regards  
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DATA COLLECTION FORM 
 
INTRODUCTION 
This questionnaire form is intended to assess the impact of isoniazid preventive therapy on 
tuberculosis incidence among HIV infected patients. The study is being conducted at Zeweditu and 
Yekatit 12 hospital in Addis Ababa, Ethiopia. The information will be collected through reviewing 
secondary data in the ART clinic. The privacy and confidentiality will strictly be secured throughout 
the research process. All the information will be numbered and coded and the names and 
identification address will not be used during the review and analysis. If the report of results is 
published, only information about the general group will appear. This information is intended to 
contribute to the existing knowledge of IPT effectiveness by comparing the incidence of TB among 
HIV infected persons receiving INH prophylaxis and those don‘t taking in Ethiopian context. 
Besides, it will provide information on program implementation and its challenges for health 
planners and managers to strengthen IPT services. Moreover it will have a paramount importance 
to curb the horizon of the disease.  
Date of review _____ Day _____ Month _____ Year 
Name of the reviewer ________________ Signature of the reviewer ______________ 
Time started __________________ Time ended _____________________ 
Name of the supervisor _______________Signature of the supervisor______________ 
Date______________________ 
 
Total number of records reviewed____________________________ 
 
Reviewed patient card number from________________ to_________________________ 
 
Result  
a) Completed_____________ 
b) Incomplete_____________ 
c) Excluded______________ 
Action taken for the incomplete data (please use additional blank paper if the space provided is not 
enough) ______________________________________________________________ 
________________________________________________________________________  
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STANDARDIZED QUESTIONNAIRE 
Part I: Baseline information (to be filled from ART clinic intake form)  
SECTION 1: SOCIO DEMIOGRAPHIC CHARACTERSTICS  
 
NO QUESTIONNAIRE/VARIABLE CODING CATEGORIES Remark 
101 Age  -------------------------------------  
102 Sex 1. Male  
2. Female 
 
103 Marital Status 1. Never Married 
2. Married 
3. Separated  
4. Divorced 
99. Widowed 
 
104 Educational status 1. No education 
2. Primary 
3. Secondary 
4. Tertiary 
 
105 Religion 1. Orthodox 
2. Muslim 
3. Protestant  
4. Catholic 
99. Other ( Specify) ------------------  
 
106 Occupational status  1. Farmer 
2. Merchant 
3. Go‘vt employee 
4. Non-go‘vtal org employee 
5. Day labourer 
6. Jobless 
Other ( specify)------------------- 
 
107 Region  1. Tigray 
2. Afar 
3. Amhara 
4. Oromiya 
5. Somiali 
6. Benishangul Gumuz 
7. SNNPR 
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8. Gambella 
9. Harar 
10. Addis Ababa 
11. Dire Dawa 
 
SECTION 2: BASELINE CLINICAL, LABORATORY AND TREATMENT INFORMATION  
NO QUESTIONNAIRE/VARIABLE CODING CATEGORIES  
201 Past opportunistic infection 1. TB  
2. PCP 
3. Cryptococcal meningitis 
4. Kaposi Sarcoma 
5. Oral candidiasis 
6. Toxoplasmosis 
7. Herpes zoster 
8. Other ( specify)  
 
202 Screened for HIV/TB smear 1. Yes__________  
2. No___________ 
 
203 If ―yes‖ to Q 202 Date_____/____/____  
204 If ―yes‖ to Q 202, result 1. Not determined 
2. Negative 
3. Positive 
4. Positive +1 
5. Positive +2 
6. Positive +3 
7. Unknown 
 
205 TB treatment  1. Yes 
2. No 
 
206 If ―yes‖ to Q 205, treatment completed  1. Yes 
2. No 
 
207 If ―yes‖ to Q 205 1. Date started____/____/_____ 
2. Date Completed _____/____/____ 
 
208 If ―yes‖ to Q 205, regimen  1. Not determined  
2. 2SRHZ/6EH 
3. 2HRZES/1HRZE/5HRE 
4. 2HRZE/6EH 
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209 Post treatment smear 1. Sputum smear positive ___/__/___ 
2. Sputum smear negative___/__/___ 
 
210 HIV test 1. Yes 
2. No 
 
211 If ―yes‖ to Q 210, date   Date ___/___/____  
212 CD4 test      1. Yes, Date___/____/____ 
        Result______________ 
2. No         
 
213 INH 1. Yes 
2. No  
 
214 Symptoms screened  
  
1. Chronic cough 
2. Night sweets 
3. Dyspnea 
4. Weight loss >10% 
5. Fever > 1 month 
 
215 Physical examination  
 
  
Lymph nodes 1. Normal 
2. Abnormal 
 
Chest  1. Normal 
2. Abnormal 
 
216 If ―yes‖ to Q 213,  1. Starting date ____/____/___ 
2. Completion date __/___/____ 
3. Discontinuation ____/___/___ 
 
217 WHO clinical stage of HIV disease 1. Stage I (___/____/___) 
2. Stage II (___/____/___) 
3. Stage III (___/____/___) 
4. Stage IV (____/____/___) 
                 DD/MM/ YY 
 
218 Did the patient evaluated for TB/cough 1. Yes 
2. No  
 
219 If ―yes‖ to Q. 217 1. TB sputum smear result 
2. Chest X ray result__________ 
 
220 Did the patient need prophylactic 
medications 
1. Yes 
2. No  
 
221 INH prophylaxis  1. Start date____/_____/_______ 
2. Discontinue____/___/______ 
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SECTION 3: SOCIAL CONDITION  
NO QUESTIONNAIRE/VARIABLE CODING CATEGORIES REMARK 
301 Employment status  1. Working full time 
2. Working part time 
3. Not working/studying due to illness 
4. Unemployed 
5. Other specify_______________  
 
302 Living home 1. Number of rooms___________ 
2. Number of people in the household 
________ 
 
303 Religious/supportive care  1. Yes 
2. No 
 
304 If ―yes‖ to Q 303, religious conviction  
 
a. Muslim 
b. Orthodox  
c. Protestant 
d. Catholic 
e. Other specify____________ 
 
305 If ―yes‖ to Q 303, community support/HIV 
support group 
1. Yes 
2. No 
 
306 Did anyone else know about your HIV 
status 
  
Family 1. Wife/husband 
2. Own child (ren) 
3. Parent(s) 
4. Brothers (s)/ Sister(s) 
 
Other 1. Relatives 
2. Friends 
 
307 Spouse condition    
1. Condition of the wife/husband a. Healthy 
b. Chronic ill 
c. Dead 
d. Unknown  
 
2. HIV tested (result) a. Not asked 
b. Negative 
c. Positive 
d. Unknown  
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3. TB (result) a. Not asked 
b. Negative 
c. Positive 
d. Unknown 
 
4. Was/is on TB treatment  a. Yes 
b. No  
 
 
SECTION 4: HEALTH EDUCATION, KNOWLEDGE AND RISK BEHAVIORS (to be 
filled from ART Adherence counselling form) 
NO QUESTIONNAIRE/VARIABLE CODING CATEGORIES  
401 Attended HIV related health education 
session/s in the past 
1. Yes 
2. No  
 
402 Attended HIV related counselling 
session/s in the past 
1. Yes 
2. No 
 
403 Understanding of HIV disease  1. NA 
2. – 
3. + 
4. ++ 
5. +++ 
 
404 Understanding of HIV transmission  1. NA 
2. – 
3. + 
4. ++ 
5. +++ 
 
405 Understanding of prophylaxis and 
treatment of OIs 
1. NA 
2. – 
3. + 
4. ++ 
5. +++ 
 
406 Addiction    
a) Tobacco  1. NA 
2. – 
3. + 
4. ++ 
5. +++ 
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b) Alcohol  1. NA 
2. – 
3. + 
4. ++ 
5. +++ 
 
c) Soft drugs ( e.g. Chat, Shisha, pills.. 
etc) 
1. NA 
2. – 
3. + 
4. ++ 
5. +++ 
 
d) Hard drug (e.g. cocaine, morphine, 
IV drugs...)  
1. NA 
2. – 
3. + 
4. ++ 
5. +++ 
 
 
 
PART II: FOLLOW UP INFORMATION (USE HIV CARE/ART FOLLOW UP FORM, ART 
and PRE ART REGISTER) 
SECTION 5: FOLLOW UP INFORMATION  
NO QUESTIONNAIRE CODING CATEGORIES REMARK 
501 Date confirmed HIV+ _____/____/____  
502 Type of HIV test 1. Rapid test 
2. ELISA 
 
503 WHO staging  3. Stage I 
4. Stage II 
5. Stage III 
6. Stage IV 
 
504 TB screened  1. Yes  
2. No 
 
505 If ―yes‖ to 504, result  1. Positive 
2. Negative 
 
506 TB prophylaxis  1. Yes  
Drug_________ duration_________ 
2. No  
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507 Opportunistic infections 1. Pulmonary TB 
2. Extra pulmonary TB 
 
508 TB treatment  3. Yes 
4. No  
 
509 CD4 (mm
3
)/TCL ________________ date____________  
510 ALT/AST ________________date_____________  
 
 
PART III: TB TREATMENT OUTCOME (USE TB REGISTER) 
SECTION 6: TB TREATMENT SUCCESS INFORMATION  
NO QUESTIONNAIRE CODING CATEGORIES 
 
REMARK 
601 Initial diagnostic AFB result 1. Positive   
2. Negative  
3. Not done   
 
602 Classification of the patient 1. Smear positive PTB  
2. Smear negative PTB 
3. EPTB   
4. Other (specify)__________ 
 
603 Category of the patient  1. New  
2. Relapse  
3. Failure  
4. Defaulter  
5. Transfer in  
6. Other (specify)_______________  
 
604 Treatment given during the 
intensive phase  
1. 2SRHZ 
2. 2HRZES 
3. 2HRZE 
4. Other (specify)________________ 
 
605 Dose of the drug during the 
intensive phase 
___________________  
606 Sputum smear result during the 
2
nd
 month of treatment 
1. Positive  
2. Negative   
 
607 Drug given during the continuation 
phase 
1. 6EH  
2. 1HRZE/5HRE 
3. Other ( specify)____________ 
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608 Dose of the drug during the 
continuation phase 
____________________  
609 Is AFB done on the 5
th
 and 7
th 
/11
th
 1. Yes  
2. No (skip to 611) 
 
610 If ― yes‖  to Q 609 the result  1. Positive  
2. Negative 
 
611 Treatment outcome of the patient 1. Cured  
2. Treatment completed  
3. Died  
4. Treatment failure  
5. Defaulter  
6. Transfer out  
7. Other(specify)_______________ 
 
612 Completeness of the registration  
form 
1. Complete  
2. Incomplete 
 
 
 
 
